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1. INTRODUCTION: 
1.1. Importance of Chronic Obstructive Pulmonary Disease (COPD) 
From recent statistics (79,59) it has been concluded that COPD is the most common lung 
disease in the United States affecting almost 16 million people. The mortality is rising, 
COPD is the fourth most common cause of death in USA after myocardial infarctions, 
cancer and stroke (91). 
COPD is clearly under diagnosed in the early stages (101). Early smoking cessation would 
have an enormous impact on the progression of the disease (7,24,25,58,106). 
This was independently proven by the National Health and Nutrition Examination Survey III 
1988-1994, which included 16 084 patients undergoing a questionnaire and full lung 
function studies, and a huge European Study (27,79,116). Europe and America see COPD 
as a major health problem. COPD is the only disease among the top leading ones, which is 
rising in prevalence and mortality (117). It is already among the twelve leading causes of 
disability worldwide. Estimations state that by the year 2020 COPD will be fifth among the 
conditions, that will be the most burden to society considering HIV - and other infectious 
disease epidemiology (92). 
In developing countries, like South Africa, we see a similar trend Hard data is difficult to 
get, but several observations in the past and the recent survey by Ehrlich, White et al. (40) 
demonstrate the importance that COPD will have in future affecting the health of millions of 
South African. 
The most important risk factor for COPD in developed countries is tobacco smoking, 
although genetic predisposition, early childhood respiratory infection, passive smoking, 
occupational exposures and outdoor air pollution playa role (12,25,123). 
In developing countries, like South Africa, COPD is also on the rise mainly due to the same 
risk factors as increasing tobacco consumption and people getting older (risk of COPD 
increases with age). 
The smoking rate in 1998 was 42% for men and 11 % for women, which translates as more 
than 7 million South Africans 15 years or older smoke regularly. Higher smoking rates have 
been observed in urban areas, more educated groups smoke less than their less educated 
counterparts. Tobacco consumption is higher among coloured men and women and the 
lowest among non-urban Africans (118). 
In their recent survey Ehrlich, White et al. (40) and Bumgarner (26) identified additional 
risk factors, which playa role in SA, those being: 
Indoor pollution, chronic infections such as TB and the combination of sub optimal nutrition 
and respiratory tract infections early in life as well as occupational air pollution (i.e. dust, 
mining). 
There is little data regarding accurate morbidity and mortality for emphysema in SA, mainly 
due to limited access of the population to health care, lack of early diagnosis and 
unavailability of spirometry for most of the population. The reporting and certification 
system lacks completeness. 
The figures available indicate, that during the 1980's total mortality from chronic lung 
disease rose, whereas that for acute respiratory infection fell, in 1990 they both were lying 
around 4 percent of all deaths. Death rates were much higher among the white and coloured 
population group than the African race (40). 
Morbidity data is gained from cross-sectional surveys of selected population. Wicht et al. 
(133) demonstrated a high prevalence of COPD of a white population sample in Cape Town. 
The data from Ehrlich and White indicate a prevalence of2-3 % in men aged less than 44 
years. In women of this age group it was slightly higher, but a sharp increase to 6.5-8.5 % 
was noted in men over 44 years. These figures are comparable to a self-reported diagnosis 
for chronic bronchitis and/or emphysema in America of 6.2 % (124). 
Urban rates of reported emphysema/bronchitis were higher than non-urban rates. 
The association with education is complex. Among men the rates for people with the least 
and most education were somewhat higher than those with intermediate education. Among 
women, the trend was for those with highest education to report the highest prevalence of 
emphysema/bronchitis (10.6 %). The highest rates were among the white race. 
Exact prevalence figures are not possible to obtain, because lung function testing is essential 
for exact evaluation of emphysema. The recent survey (40) however showed a few 
interesting observations: 
1. Confirmation of the high impact of smoking 
2. A specific group of fast decliners 
3. A significant risk factor is exposure to indoor pollution from cooking fuels 
4. Occupational air pollution including mining, construction, manufacturing and agriculture 
playa significant role in the development of COPD 
5. A strong impact on COPD due to previous TB 
1.2. Pathology, Pathophysiology and Physiological Impairment ofCOPD and 
Emphysema 
COPD is a disorder characterized by reduced maximum expiratory flow and slow forced 
emptying of the lungs, which does not change markedly over several months and has to be 
distinguished from asthma where air flow limitation is usually variable and reversible over 
short periods of time. 
The British Thoracic Society (23) defines COPD as follows: 
"COPD is a slowly progressive disorder characterized by airflow obstruction (reduced FEV 1 
and FEV IIFVC ratio) that does not vary markedly over several months of observation. Most 
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of the lung function impainnent is fixed, although some reversibility can be produced by 
bronchodilator (or other) therapy." 
There is general agreement that airflow limitation in COPO is the result of increased 
peripheral airway resistance, secondary to a mixture of small airways disease and 
emphysema (30). 
Three conditions contribute to the picture of COPO: 
1. Chronic bronchitis: 
Chronic bronchitis is an inflammatory condition, clinically apparent as chronic cough and 
recurrent increase in bronchial secretions (mucus hypersecretions) (61). It becomes more 
clear in recent years, that mucus hypersecretion and sputum volume are associated with a 
decline in FEVt, increased hospital admissions and increased mortality (103,126). Mucus 
does have a detrimental effect on the stability of small airways in COPO. 
2. Chronic bronchiolitis: 
Chronic bronchiolitis (small or peripheral airway disease) is an inflammatory condition of 
small bronchi and bronchioles, in which there are predominantly C08+ and pigmented 
macrophages involved. 
3. Emphysema: 
Emphysema is an inflammatory condition of the alveoli in which T .lymphocytes, 
neutrophils and pigmented alveolar macrophages are involved associated with the release 
of excessive amounts of elastase. Emphysema is a result of an imbalance between 
proteolytic enzymes and protease inhibitors in the lung. Lung tissue, primarily elastin, 
undergoes repeated destruction, synthesis and degradation (68). In addition an excessive 
oxidant burden degrades the nonnal protease inhibitor screen. 
Anatomically emphysema is defmed as permanent destructive enlargement of airspaces 
distal to the tenninal bronchiole without fibrosis. 
There are two basic types corresponding to a persistent enlargement of the bronchiolar and 
alveolar portions of the respiratory acinus. 
The bronchiolar (=centrilobular) and the alveolar emphysema. The panacinar emphysema 
involves the entire acinus (Figure Id). It is often difficult to distinguish between confluent 
centrilobular and panacinar emphysema. 
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Thc lung internal surface for a 6000 ml IUllg is approximately 70 ml, ill alveolar emphysema 
Ihe mean value is decreased to approximately 46 ml, whereas in bronchiolar emphysema it 
is less reduced (approx 6 1 ml), which C'quals 87"10 of thc figure in a normal lung, 
The same applies to the number of alvcolar spaces. which is markedly reduced in alveol!lJ' 
emphysema. less pronounced in bronchiolar emph>'scma. It seems to be. that the bronchiolar 
("'cenlrilobular) emphysema is more likely to give rise to serious pulmonary hypertension. 
Dcvelopment of pulmonary hypertensioll in emphysema is mainly due to the development of 
museu lariz~'<1 pulmonary arterioles and therefore increased pulmonary vascular resistance 
(Figure 4) and not so much due to loss of the pulmonary bed or fibrosis. It seems to be more 
periodic in nu!Ure, unlike the severe pUlmonary hypertension in ocqu)red and congenital 
hean disease. occurring during anucks of rcspirntory mfection or fluid retenuon. 
It is believed, that this museu larization of the Icrminal portions of lite pulmonary artery tree 
is due 10 hypoxia and il is not only found in cenlrilobular and panacinar emphysema. but 
also \n other chronic hYPOXIC conditions like Monge's disease or severe kyphoskoliosis (52, 
53). 
Hypoxic hypertensive pulmonary vascular disease ~ems 10 be p3rtially or fully reversible. 
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Au""ay resistance In rnlphysem:i: 
It has been demonstrated by Hogg n al., that in both centrilobulllr and panllCmar etnph)·sema 
there is an LIIcreased resistance to :Iirflow in 1I.I\"WlI}S less than 2 mm (57). 
In centrilobular emphysemail is mainly due to inflammation llIld nntro\lmg orthe bronchio-
les, \lhereu in panocinar emphysema the bronchioles :ire mT\'ly affected. E,·idence of 
chromc mllammauon in main. lobar and segmen131 bronchi was present in all cases or 
emphyxmll. 
Cathctcr studies sho\led, Ibat there " ·eT\' two mechanisms or airway reststance One was 
Situated In the WUl11er llJI"W ay nnd was T\'llIl.i\"cly fil\:ed. The other ooe was situated in the 
larger airways and became greally increased during c l\:pirdlion. 
11 \las shown. tlult in a normal lung the .5IIlallcr airw ays only contrihute approx 25% to total 
LIlrway resistnnce. \lhereas in pal ients wilh emphysema there is an iocT\'as(' in 10lal ai rv .. ~y 
resiM:lncc. the smaller ai""'ays now cOnlnbutmg as much as 90 % (52). 
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Soch obsef"\'ations suggeSI that. as far as an incrca5l:d aino. ... y rtSlstance is e01K:(T11cd. il is the 
abnonnality ofthc small bronchi aoo bronchioles which is primary. Inc expmuory collhpsc 
of larger airways bein!! sc<:ondary. 
The flow related collapse of the sm:lIler 3Ino.'aYS occws more easily in emphysema. a 
phenomenon also called ai r Ir~pping: 
II is mainly due [0 the destruction ofparcnch),ma and rcsuhs in loss of clastic recoil. which 
usuall) keeps thl,> 5f11allcr airway open. The conccpt of th t NJual pr"uu~ point applies as 
follow,.; 
ThI,> canil3li1inous aino.-ays h,n'e a considcrublc siructural resistance to collapse. airways 
bc:)'ood gentTution II havc no structuml rigiditY!U1d are fully de~ndanl on truclion on their 
walls from clastic l\.'1.:oil orthe lung 1i~suc they are CTIlbedded (97). They collapse when Ihe 
trrul5f11U/l1.I pressure re,'c!'#s (Fi¥urc 5): 
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In summW'y aflhc pre"ious]y oollined mechanism lhese functional abnonna/itics result from 
mflammation of small conducting airways C311'ling them 10 be narro"'cd and cloSt' 
prematurely (14,3557.100). There is d..-slruction of lung tis~ue distal 10 the terminal 
tronchioles. which interferes y,ith the supponi\'e function orthe peripheral airways (28.109) 
and shifts the equal pressure pomt, and dccre;lses the clastic recoil force rcsponsihlc for 
driving air out of the lung (84). In these circumstances the lungs hyperinnate. 'n,is 
overinfbtion grossly impairs the abil it y of thc respiratory muscks 10 gcncmte reqUired 
force. The diaphragm oceomcs lowcr and nalll'T and the apposition of the diaphragm to the 
lower rib cage di minishes. Inspil1ltion then leads 10 an inward pull on the lower rib cage. 
This diminishes the force gencrating IIbili t) of the' inspil1ltory muscles and increases dyspnca 
through rut aWllfencss of Incrc llSCd ncurnl stimulation to , 'cntilatc and eventual fatigue of lhe 
rc5pil1llory muscles {III. 74). n,e hypennflated lungs IICt mechanically on both Ihe alna and 
\'entricles 10 limit thcir respeclive diastole fiJli~ especially during exercise (29). In addition. 
in pallCntS witb marked overinflation. inspiration results in a decrease In \'eoous return to the 
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heart rather than the normal increase (94). The net result is a marked reduction in mixed 
venous oxygen tension and cardiac output leading to increased dyspnea (89). 
1.3. Medical management of Emphysema: 
From the pathophysiologic descriptions it is clear, that medical treatment has a limited role 
in the management of emphysema, there is no medical cure. The medical treatment of 
emphysema consists of a combination therapy with bronchodilators, corticosteroids and 
treatment of acute exacerbations of infections. It has been summarized in a recent consensus 
report from the American Thoracic Society and the Canadian Thoracic Society (5,31,62). 
Medication and smoking cessation do have a supportive affect on the symptoms, but cannot 
reverse the amount of destruction. Exacerbations and infections can be successfully treated 
with antibiotics and/or steroids. Influenza vaccination is advisable. Nutrition and protein 
replacement in patients with alpha 1 anti-trypsin deficiency may be helpful. 
Cardiopulmonary rehabilitation can improve exercise capacity and dyspnea, the values of 
spirometry or gas exchange are not altered. Long-term home oxygen is often the only 
therapy, which improves quality of life and survival in these patients, but is a major expense. 
The goals of medical therapy include diagnosis, assessment of severity and evaluation of 
comorbid disease as well as dealing with complications. Patients should undergo regular 
surveillance to prevent further decline, to optimise pulmonary function and reduce disability. 
Despite all these efforts of aggressive and appropriate medical treatment the patient's 
symptoms, effort tolerance and therefore quality of life decline within years, resulting in the 
endpoint of therapy being often only lung transplantation. 
1.4. Rehabilitation program: 
Pulmonary rehabilitation grew out of an attempt by physicians to use breathing control and 
exercise to help chronic lung disease patients cope with dyspnea. The consensus definition 
from 1993 established at a workshop of the National Institutes of Health (NIH USA) states: 
"Pulmonary rehabilitation is a multidimensional continuum of services directed to persons 
with pulmonary disease and their families, usually by an interdisciplinary team of 
specialists, with the goal of achieving and maintaining the individual's maximum level of 
independence and functioning in the community." (43) 
It is agreed upon by all participants that pulmonary rehabilitation is an essential part before 
L VRS and should be completed by all patients prior to surgery. It not only aims to improve 
the symptom of dyspnea, but also addresses psychosocial problems and motivation. 
In selected cases it should be offered to patients with COPD, who are not candidates for 
L VRS. Several randomised trials have proven that dyspnea is reduced and exercise tolerance 
improves as well as quality of life (2,67). 
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Pulmonary rehabilitation is organized in three phases. The first phase is the inpatient 
program, which consists of education, psychosocial support and light activity. Phase two is 
an outpatient program, which consists of a more extensive educational component, an 
exercise training program and continued psychosocial support. The third phase or 
maintenance is a continuum of phase two, but patient take responsibility for their own 
exercise program and use skills learned in phase two regarding self-management of their 
disease. Education, exercise and psychosocial support are integral components of all three 
phases, but each is adjusted to the individual patient and situation (102). 
In our study all patients underwent such a rehabilitation program prior to surgery. 
1.5. Surgical management: 
Lung volume reduction surgery (L VRS) has been advocated for patients with severe 
emphysema and marked lung hyperinflation. It is not a new technique, but experiences its 
revival recently. 
1.5.1. Bistonr: 
There is little doubt traditionally about the value ofbullectomy for bullous emphysema to 
relief normal compressed lung and consequently improve lung function. Many good reviews 
proof that point and these patients in general have a favourable outcome (4,13,33,32,46,56, 
90,110). 
Diffuse generalized emphysema represents a different entity, often accompanied by poor 
quality of life, limited survival and poor response to medical treatment. 
At the beginning of the 20th century a few different surgical strategies have been followed 
with varying success. One concept was based on elevating the flattened diaphragm either by 
the application of an abdominal compression device (Le. belts) or creating a pneumoperi-
toneum, none of which could improve dyspnea or quality of life (3, 1 05). Another ill-defined 
concept was to diminish the space of the thoracic cage and therefore counteract the 
hyperinflation of the lung and extension of the rib cage by thoracoplasty or phrenic nerve 
ablation, which most of the time led to worsening of the symptoms (95,128). 
Slightly better results in some patients could be achieved by allowing the hyperinflated lung 
to fill more space. Costochondrectomies were performed (45), but the outcome proved to be 
fairly unpredictable. Pleurectomies were performed in the hope to enhance blood flow from 
collaterals; this could never proof measurable advantages. 
Operations aiming at the nervous system. like glomectomies to reduce bronchoconstriction 
lacking the physiological reasoning and therefore could never demonstrate any improve-
ments for the patients with diffuse emphysema (l,93,36). 
These early attempts for a surgical solution all together failed and it needed new concepts to 
come one step closer to the problem. 
Brantigan was the pioneer of the idea to perform mUltiple wedge resections to reduce lung 
volume and improve mechanics. His theory was that in a normal patient the bronchi are 
relatively pliable and held open by a circumferential elastic pull of the expanded lung. In 
emphysema patients this elasticity is lost, resulting in collapse of bronchi. By reducing the 
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volwne of the lung this radial traction on the bronchi would be restored. expiratory airflow 
obstruction and dyspnea would be reduced (19-21). 
Brantigan presented his series in 1959. Kennedy (64) in 1960. for a variety of reasons inclu-
ding the 16-22% operative mortality and lack of spirometric docwnentation this procedure 
did not gain support. Brantigan received a lot of criticism from his colleagues. who found it 
hard to believe. that one can improve lung function with taking away lung tissue in a diffuse 
process, which is characterized by a loss of parenchyma (65). 
Delarue in 1977 reported a series of surgical interventions for patients with emphysema and 
dyspnea, he also had a 20 % mortality (38) and the enthusiasm for surgery remained low. 
In the late 1980's surgery for emphysema resurfaced using laser or argon beam coagulators 
(71,130). 
It took as long as 1995, when Cooper et al revived Brantigan's concept, especially after 
some observations in his lung transplant patients. Firstly he saw chest wall configurations of 
emphysema patient returning to almost nonnal after having received a smaller lung. 
Secondly he found adequate gas exchange with single lung ventilation while these patients 
underwent single lung transplants and therefore was encouraged to operate on these severely 
compromised patients. 
In his initial series twenty patients underwent L VRS bilateral via a medianstemotomy and 
his early results were encouraging (33). 
1.5.2. Different techniques used internationally: 
Laser ablation: 
Various lasers have been used (Table 1). marked variation in technique is noted (C(h 
versus Nd:YAG. free beam versus contact). Widespread use by Wakabayashi and his 
colleagues did not convince the thoracic fraternity. Two prospective randomised studies by 
Hazelrigg (54) and Little (73) showed only small improvements in lung functions with the 
laser technique, not being anywhere near to the early results of Cooper et al. 
Problems with prolonged air leaks occurred in over 50% of cases, and moderate to severe 
subcutaneous emphysema developed in 45% of cases (73). 
Mc Kenna showed in a prospective randomised study a clear advantage of the stapler versus 
the laser treatment (83). Therefore most groups have abandoned laser ablation. 
Tablel: Reported experience with laser reduction surgery (54) 
Reference Patients Laser Follow up FEV1 ET improvement Operative 
Nr. improvement mortality 
130 22 CO2 1-3 m x 0.74 -1.06 504 - 8 min 9.1% 
131 443 ND:Yag 12-39 m 23-31%pred 87% 4.8% 
55 141 ND:Yag 3m x 0.80±0.30 846ft in 6min 5.78/0 
83 33 ND:Yag 6m 6 ±3% O.(}% 
63 10 ND:Yag 20% 
22A 16 ~ 1-3 m 0.2±0.2 21% 
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Combined technique: 
Eugene et al (41) and Wakabayashi (130) combined Nd-Y AG laser ablation with stapled 
resections and came up with slightly better results concerning lung functions and relief from 
dyspnea compared to only laser ablation. Both reports do not provide details regarding the 
extent of either resection or laser ablation and therefore reproducibility and fair judgement 
of this technique is impossible. 
Mortality was acceptable (-6%), increase in FEV 1 was around 30% and the patients noted 
subjective improvements. 
Prolonged air leaks occurred in almost 50% of patients, reflecting the same problem 
mentioned above with the laser ablation. 
Unilateral versus bilateral approach: 
Most groups found a bigger improvement in patients undergone bilateral procedures 
(54,82,83,114). 
Mc Kenna in his study found an even higher mortality in the unilateral group, which is 
supporting arguments pro the bilateral approach (83). The complication rate was similar in 
both groups. 
In patients with only unilateral target zones or contraindications (previous thoracotomy, TB, 
pleurodesis etc.) a unilateral approach is indicated. 
Thoracoscopic L VRS versus mediansternotomy: 
Some investigators thought that the minimal invasive approach would be of benefit to these 
fragile patients. 
Early reports from Keenan (63), Mc Kenna and Naunheim showed that thoracoscopy is a 
feasible option with mortality rates between 2.5-5,3 %, significant improvements in FEV 1 
(27-35%) and marked decrease in the use of oxygen (82,95,96). 
As mentioned before the bilateral approach seems to be superior (82,83). Other authors 
report similar success (48,16,22). 
Other experienced centres report similar results with L VRS performed via a median-
sternotomy (8,33,37,87,88). 
Arguments for bilateral VATS are: 
all areas of the lung can be accessed 
less pain 
shorter hospital stay 
Arguments for mediansternotomy: 
less airleaks and better control over bleeding and leaks 
- remodelling of the remaining lung more physiologic 
- target areas are better to identify 
less costs 
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Reports indicate equal short-tenn outcome. A slightly better long-tenn outcome in the 
mediansternotomy group is noted, but that can be due to the fact, that the teams, who now 
have a 5-6 y follow up, started doing L VRS via mediansternotomies. 
Acceptable results have been demonstrated with both techniques (10,33,63,83,87,88). 
Wisser et al demonstrated equal results with both techniques in tenns of functional 
improvements and complication rates (135). 
Lung transplantation: 
Lung transplantation, single or double, provides excellent palliation for selected patients 
with advanced emphysema. 
Emphysema is in fact the most common indication for lung transplantation (51). 
Nevertheless several problems arise from this approach. First there is at least a 1-2 year 
waiting period for an organ, the annual mortality for patients on the waiting list is 10%. 
Second, the requirement of immunosuppressive medication does have negative effects like 
hypertension, diabetes, infections and an increased risk ofhaematologic malignancies. 
Nearly everybody will suffer from significant infectious complications in their lifetime. 
Third, transplantation, the medication and follow up are extremely expensive. Fourth, 
although short-tenn survival following lung transplantation is in the range of9001o in big 
centres, 4-year survival is only 30-40% (51,99), largely as a result of obliterative 
bronchiolitis. 
Methods used in GSH: 
As a conclusion of the literature review we decided on the following approach: 
All our patients were operated in a standard fashion via a mediansternotomy, bilateral wedge 
resections aimed to reduced the lung volume by approximately 30%. No pericardial 
buttressing was used, but GRF glue was applicated to prevent air leaks. 
The team consisting of the pulmonologists, surgeons, anaethetists and experienced nursing 
staff ensured correct indications, technique, pain relief and best postoperative care in ICU. A 
thoracic epidural catheter was inserted in all patients preoperatively, enabling us to extubate 
all but one patient in theatre postop and to transfer them to the ICU spontaneously breathing 
on a 40% oxygen mask. The surgical technique is described in detail in the following 
chapter. 
1.5.3. Current status ofLVRS: 
Recent enthusiasm for the procedure has resulted in a large number of case reports claiming 
dramatic results. Meanwhile there are several trials published, which confinn Cooper's 
findings from 1995 (33,34,39,47,81,85,107,108,112,113,119), most of them showing a 
benefit for patients with severe emphysema regarding lung functions and quality of life. 
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Nevertheless L VRS is high risk and expensive. It has yet to be evaluated in a prospective 
randomised trial enrolling a large number of patients. This is under way as a combined effort 
of several universities in Canada and England at the moment. The University of Cape Town, 
respectively the Department of Cardio-Thoracic Surgery and the Respiratory Clinic will 
participate in the study. Results are expected in a few years, patients recruitment is behind 
schedule. Until these studies are published one has to rely on data provided by small series. 
Until now a few questions about the best approach, technique and patients selection seem to 
be solved. As described in the previous chapter the bilateral approach is superior (39,85, 
114), the laser technique is abandoned and there is equal distribution in the surgical 
fraternity favouring mediansternotomy or thoracoscopic methods. 
Two groups used a plication- or loop techniques instead of stapling the lung (72,121) via the 
thoracoscopic approach resulting in multiple small wedge resections. Sabanathan empha-
sizes that the lung resection ( > 30%) and not the operative approach is critical to the success 
of the operation (108). Very little discussion about the patient selection in the recent 
literature indicates, that most inclusion and exclusion criteria are agreed upon. 
L VRS as an alternative or bridge to transplantation is regarded as a viable option by many 
authors (51,95,125,136), even as a salvage operation in chronic allograft rejection (111) or 
LVRS in the native lung post single lung transplantation (6). 
Nevertheless the topic is still controversial until big prospective randomised trials with a 
reasonable follow-up period are published. Many questions remain and are subject of several 
multicenter trials (87,88,125), which will not produce any results before the next 2-4 years. 
We therefore still rely on results from small series. They seem to show following trends in 
short- and median follow-ups after LVRS (34,39,47,81,85,95,96,107,112,113,119): 
relief of breathlessness ( dyspnea) 
improvement in FEV!. FVC and RV 
improvement in quality of life 
decrease in oxygen dependancy 
slow decline of lung function after one year parallel to the natural history 
clinical and physiological improvements after> 3 years (48) 
- L VRS is palliative in nature 
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2. GROOTE SCHUUR EXPERIENCE: MATERIAL AND 
METHODS: 
2.1. Study Design: 
We perfonned LVRS on ten patients so far, starting in 1995. The relatively small number is 
consequence of careful patient selection and financial constraints. 
We retrospectively analysed our data to detennine the impact of LVRS on airflow 
limitation, symptoms of breathlessness, quality of life and costs in patients with severe 
emphysema. Therefore the purpose of this study was the following: 
• Assessment of pUlmonary physiology, exercise tolerance, morbidity and mortality of 
L VRS as practiced in Groote Schuur Hospital (optimal medical management including 
respiratory rehabilitation followed by surgery) in a retrospective study. 
Inclusion and exclusion criteria, modified techniques and postoperative 
Management, short- and long-tenn results over a period of 5 years are reported 
• Evaluation of the 
a: Cost effectiveness of L VRS in a state hospital and its impact upon 
b: Assessment of Quality of Life 
to investigate, whether L VRS is an acceptable fonn of treatment for severe emphysema in 
countries like South Africa. 
Limitations of this study are the relatively small number of patients, but all were selected 
according to our strict inclusion- and exclusion criteria, and therefore it is a relative homo-
genous group. No change in surgical technique or selection took place over these 5 years. 
The second problem is, that the follow up data show significant gaps, which are mainly due 
to long distance travelling necessary for 5 patients and cost constraints in the SA health 
system. Especially the plethysmography values could not be obtained on a regular basis, 
making these results worthless for statistical analysis. 
Despite the fact, that the quality oflife scores were evaluated retrospectively and patients 
tend to forget the downsides and hard times in life easier than the successes, the reliability 
and accuracy of these questionnaires was confinned when compared with the physician's 
notes in the folders. The almost unifonn results for the six patients evaluated reflect the 
general outcome in tenns of quality of life. 
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Participants: 
Four males and six females, the age ranging between 44-59 years with disabling 
dyspnea due to severe emphysema. 
2.2. Inclusion- and exclusion criteria: 
Inclusion Criteria: 
Radiographic evidence of emphysema, 
Disabling dyspnea 
Air flow limitation (FEVI less 35% predicted), 
Gas trapping (TLC > 120%, RVffLC >60%), 
Hyperinflation RV > 200% predicted 
Ability to complete preoperative rehabilitation program 
Cessation of smoking 
Exclusion Criteria: 
Absolute: 
Age >75 y, 
Severe obesity, 
Hypercapnia (pC02 >55 mmHg), 
Isolated bulla> 20% of hemithorax, 
Malignancies and significant medical illnesses 
Relative: 
Ventilated patients, 
Chest wall deformities, 
Previous thoracotomy or pleural disease (including previous PTB), 
Bronchiectasis 
Asthma 
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2.3. i\h'l hol.b u§Cd in G roule Schu u r lIospibl: 
10 palients w~ suitable for L VRS according 10 the abov~memioncd inclusion and 
e~dusion criteria. !he palienEs' dala 10 be demonstrated ill Tab\C' 4 (~ page 27): 
Foctors ussessed were pre- and poSlOpmuive forced expinuory volume in 1 second (FEV I)' 
furttd vital capacity (FVe). lotaIlung capacily (11.C). residual ~'OIUITIe (RV), pQz. pCOl, 
carbon mo~xidc dilTusing capacil.y with a single bn-ath me\h>d (TLCO) and the 6 min walk 
,~. 
A lhoracil: epidural talheler was pbced and II T I·TS bloc!,; was eStablished on lhe o""le 
paliem. 
All LVRS was perfonned under general lUlileSl.hesia usng II double lumen tube ( Figure 6). 
peak implMllory pressure Wa.'l limited 10 < 20 em H~. I:E - 1:4. 
All palients ,,-ere operated via a median sternotomy in supine posicion. the p3lienlS weTC 
\'emilated wilh 100% O:z for 20 min 10 preo)()'gcnale and 10 demonstl1llC IlrealJ ofhigh 
vemilationlperfusion miSmlllclI. because these areas will deflatc a1vwl.'f oller lhe luni is 
wnled and IlIlowed to collnpse. The non c .. Uapse<! an:as were primarily -elected as tllfllC'l 
Ilrea. for ~tiol\ Iud wasped with clamps (Figure 7 Ilnd FiSW"l: 8). 
Aller pr~'Collling a 90 mm stapler de\'ic.! ITA 90. Ethicon.lohnscm&Johroonl "ith GRF 
glue ( .. GeI01ioo·resoreillOl·fonmklchydc) these areas ,,-ere fl.'So,.'("\ed paying atlmion to 
regrun II shape of the remaining lung. which am fill lhe ehe .. ca~ity appropriately. 
The Slapk:d lung was remo\~-d lind the slapled edge SCIlIed with GR ... glue (F"lj;ure 9 + 10). 
avoiding eonlacl of the romUllin to olher purlS of the lunS except the stapler line. ARer 10 
min the ~luo: had SCI and thl.· IUII¥ WllS carefully n:c'xp!lQIkd Il!ld checJ.l.-d !Of" k'a/( s (FigUR' 
Oil 
This procedure WIU repcal ~-d 011 too Olher side. We aillli.'d fur fCliCCt~-d aJ('a of - 30% of the 
IunS (Figure 12), Wc kR four 28 Ch dmins in ~ illl (2 on each ~ide) and elosed the chest 
" 
!'eV>lring the st ... mum Local anaesthe'Sia ,,-as ghen to the drain SIte'S and the manubnum 
Slenu. the tOOrocl" epidural was maintamed with O~5 ~~ bupi\acaine 
The palltIllS Wefe extub:HeJ In thC.:llrC' aftef reI mal of the ana~thetics. u.\ua!l~ changing to 
a $If161e lumen lube allowing !he peG,. I\) corne down WId transfer the p.3tient awal..e hlthe 
ICU. POS\opC"l1Ihle monltonng and lreatment included J houri) blood j;aSeS, 0:' satUf3l.Jon 
monitllring. urln3r}' C3lheter and thoracic epidural for adequate Wl3lgesia Md o:<)gen masl.. 
hurnidific.;!tion. nebuliulUon and npcrirnced p/tyslOther.jPY for sufficient osn;enltion of 
the SJXmtanC'(>usl~' brealhing pal1c-nl (FigUR" 14). 
L\ 'RS was ptTformed as described in the previous ch,lpler b) 1 .... 0 suq:emu. the techniqUl: 
lIas nut altered or changed for the len C~5 
" 
" 
Flj!LIre II Cor.r"1 .-"I' .... ~ .. of"," I"", . ~ .. 'i><: JI ... h.u dncd 
" 
fill .... 1). 1'f«l!I<"'''''. CXR ' -r ond 100 .... (Itll) ond 6 " . . I<s [10""'1>0'"''''' ("JIlt). A nwk<d d,fTcrrncc ;. ""led in ..... 
<1f lhe: dUtph"" ... Ion, "0(",1\<,> .nd the: _..,.1\01 _. 
" 
" 
2.4. COSI analysis: 
For the COSt nnalysis recent prieine with the best values available 10 a state hospital (year 
2000) and lor fees according w the MASA guidelines were used. The scale ofbcnefil values 
were appl ied [or all procedures and diagnostic tests. as well as for most ofthc consultation 
fees, Only where the price available to GSH was lower than the scale o f benefit fees we used 
the low~'f price (i.e. for medication and some laooralory items). The costs for each patient 
IT able 9) were retrieved froln ,he ["ldeTs .. nd mi<;:mfi tms and indi v;dually calculated. No 
estimations \\-'ere applied. 
The one patient. who died on day I postoperntive. was excluded from the a\'er"Jge 
calculmion. 
To compare Ihe COSIS for patients who rccciwd L VRS with the costs of pmients with 
medicaltrcalmcnt alone we have chosen a period of5 years, becauS<." the natural hislory of 
the disease in end stage emphysema would make a longer period unrealistic and would bias 
the results in favour ofa better cost clTcctivc]1ess of the surgical group, 
Three different scenarios were calculated. based on information retrieved from the patiem's 
folders and personal experiencc of the auending pulrnonologists: 
1. An average }'ear ofa patient with severe emphysema on mcdicallreatmcm 
2. An avernge year of a piltient. who has done well after L VRS 
3 An a\'ernge year ofa patient with end stage COPO (bedridden, oxygen dep<:ndanf) 
For comparison purposes the costs orthc medication are lisled with state tender prizes and 
wholesale prices, which are more reahstic and rdkcl. wh3l1l chronic COI'O patienl costs 
over the 5-year period. 
StatiSlies: 
For the statisticaillnalyses the SPPS Base 7.S for Windows 1997 software was applied. 
Both descripti\'e statistics (± 2S0) and the paired t·lest were used for the physiological 
parameters. 
2.5. Q ua lity or l i r~: 
To assess qualit)· oflife: two innum~nls were ust<!. 
• 
Tht Medical Outoom~ Stud) Soon Form 36 (MOS SF 36) 
The MOS SF 36 is a Generic health- related quality oflifc measure . The illSll'llll1<nt is used 
"iddy to C\lI!uate health-related quality of life. It can be self or inu:rvie .... -cr administered. II 
teslS 8 domains: physical fW1CtioninG: role limitations due to physical health problems; 
bodil~' pain; social funClioning; general mental health: role limitations due to emotional 
prob!ems~ "itality. energy or fatigue and general health perceptions. 
In the MOS SF 36 ::!;cm is the "Or'St and 100 is the best score, climcal sIgnificant difference 
15 reached with a changc in score of more than 20 . 
• 
Chronic Respiratory Disease QueSli()f1naire (CRQ) 
The CRQ is an interviewer-administered quesMnnaire measuring both physical and 
emotional aspects of chronic respiratory disease. [ttests four catc:gories: d~spnea. fatigue. 
emotional function and mastery on a numerical 7 point modified Liken Scale. 
Mmimal important differe nce is reflected by a change in score o r o.s on a sc\cn-point scale. 
R change of more than I represents a clinically siGni ticant difference. 
Both mstruments"ere administered by the same intervicwcr proopernll\c and 6 months 
postoperative retrospectiyely. 
In additton the use of home o)l;ygen and the degrce ofaeti"itics arc reponcd at ditTcrentlime 
inter\lIls posIoper3tivc (Table 10). 
J. RESULTS: 
Table" gives an o\'er"iew orthe ten patients who undcr",enl L VRS after careful selection 
according to above menlionro inclusion and exclusion criteria. 
Six female and four male patients .... ith a median age of 50.8 years (range from 41- 59) were 
operated on hilau:rnlly \'ia a mcdiallSlemotomy. In 11'0'0 pali~nlS an alpha I anti-trypsin 
deficiency was knov.n. the others "e~ tested normal. 
Seven have been smokers "im a median pack year histOf)' of 37 pack years (roogc 15·100). 
all of them SlOpped smoking hefoo: the rehabilitation program staned. Three patients were 
non-smokers. 
Se,'cn patients had grade IV d}spnea. according 10 the Dyspnea score in Table 2. Ihn.-e had 
grnde IJI dyspnea Ofw 0fIC'S seveI'd)' short of breath al rest fJ\'t' used home o.~H;cn more 
than 8 h. three of them W~ absolutely bed bound. 
Table 2: Modified Medical Research Courx:il Dyspnea Sca!e (60) 
o No! troubled with breathlessness except with sU'enuous exel'dsc 
Troubled by shortness ofbrcath when hurrying un the le\\:1 or walking 
up a slight hlll 
/I Walks slo\\,er than J'C'lple of the same age on the level because of 
brcluhh,ssn .. "" Or has 10 'top (or bualh wh,m walking al own pac:c on 
Ihe level 
III Stops for breath after walking about 100 yards Of aller a few minutes 
on the lellel 
IV Too brcnthless to leallc the hous~ or breaddi:ss When dressing or 
undressing 
" 
The CT- and !'erfuslon SC3n results !"C\Caled a homogenous pattern in four CIISCS and a 
Inhomogeneous pailI'm In six patients_ describing a Cl.'fIlrilobular apJlCilfIll\ce in five. a pan-
acinar in one and a mixed t)"PC in four patients. 
3.2. MOriali!)' n d morb idi ty: 
The 30 day monality .... 11$ tOOl •. This patient was the onl y one. who could not be extubated 
dir«lly po5topcrnti\<'ly. Iii: died the first postoperati ve night due to respiratory failure. TIllS 
W1l$ the only major complication, and lead to thc death of this palient 
Of the remaining nine patients minor complication, occurred In six, main ly prolonged air 
lc:al.s or residual pneumothoraces (Tobie 3). 
T"b1e 3: Morbidity o fLVRS in GSH (1 995-1 999) 
Morbidity · 
Prolonged air Ira\( > 5 days 6 
Small aplcill pncUID010011ll[ J 
Rcthoracotomy (air kak) 
Rcspirotory troct infection 
Superfi cial \',0000 infec tion 
Sternal w'OIlnd pain 2 
• t~ 6 out of9 pauenl$. J pallenl. had no compllcalion 
The actuarial survival is depicted in Figure: IS. 
O~ patient died a few hours after surgery. In the S ycar follow up period another two 
patients died aftCf) )'urs and" )"C3f"S post L \IRS. bolh in respinllory fllliurt due: to 
endstagt ~ph)'kma. 
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Prooperati \'e ,'alues: 
Table 4 summarises FEV I , rvc, RV, nc, diffusion capacity (=-TLCO) , 6 min " ,111: tcs t 
and blood gas analys is in ~Il len patients prcopcruti\'ely: 
Table'; O~-aview OfprCOpcnili\'e da\JI ' 
PlllieDt ~ ~ Ratio · •• i I(KA) 
" 
','" ';;; -;;:; JS8 
2(VN) 21.0 6U " 5.' 
, .. 
3(MI) ,:. II 70 
4(MV) 4~ 58.' " &1:~ ';';;' ;;; 246 
5(VU8) 20.6 8",.7 " '(" 50" J85 
6(SCII) 6' " , 277 
7(NE) 11.", 
"'I'"' " IS' 15. JL8 75 
II(TM) ~ U " " l25 9(S'f) " , 3SO 
JI(SN) 
'" 
, . II 
'" 
:: , .• 2",5 
~ 
19.1 .... 
" 
, .. 
". 34.' 
'" 
• pMl bror><hodiwor rnpon~ > J~ 
• :slops "",eel",}, 
Only In one pmienl no values for residual volume (R V), 10\JI11ung cajXlCi ly (Tl C) ond 
I.h l1·usion capac,l>' (TLeD) could be eslablislled preoperative, beclluse Ihe patienl was 
unable to lolcrate thc body box Icsi . 
We liu\'c ml:en Ihe best values after broncliodil3tors, tile" + ., is iooicatmg. iftlic di lator 
response WlIS more llian 10"/0, 
In 1I\"e1"oge tlte FEV \ was 19.7 % of predicted (J 2.6% - 29.0%), llie FVC 64.6 -/0 o f predicled 
(j69% · 92 ,W.), " , Ih II ratio of 28. 
" 
The RV was on a\erugc: 27~'. hight-r clwl pmlicted ,1lIU(:$ (209"4- 356 °4). the fLC \40". 
of predle!N (111 0,. • 160"",). 
The TlCO sInale breach was 3.1.9 ". ofprediCled 122.~~· 50.60/0 ). establi$hed by che 
carilon moooxlIk dlrr""lOn mcchod 
"fhc, results oft/w: 6 nun "'1I1k tes\ preopcTlll1 \'C differed from 70 - 385 m and are oom~red 
lau:r "'lth the poSlopclllche \alues. 
Blood aIlS WlIlI)'sis rc\"eokd an avnuge pC0j of 4.38 mmH\I. (3.76 -6.1), and a pOl of9.47 
mmHg (8,6 - 12.261· 
Table 5; Blood illS analysis for 9 patimlS preopcrllli\'c' 
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For the $IOlClstiail iIIllll)'sis the:- %, predicted valucs ",'en: roundN up or down. 
Figure 16· 21 sumnllmZl." the:- ttcrnl including all a\1Illobie data of me nmc pmiems O\'cr a 
];\'e YCIil' folio", up period, The meOUl val lieS ore demonstrated as 0 square ± 2SD ]fthen: 
were leu LlI;m 3 patients IlO mcOUl 15 shown Wly more 
All physiolOl1lclI1 pal"llm<:lers are measured as thl.' 0/. predicted \'3.Iucs instead of IIbsolute 
fi~urcl. ",I\!ch repn:scnts tM adjusunentl 10 IIgC, sex and height. 
We did /I Jl1l.red sample analysis on all mcISUfemef1t$, only the slatisticall) signifiUIIC 
results lire IIlustnued ( FEV., ~dual volumc and 6 min walk lest ). 
AlllnlliuduaJ results and curves of each pWleJll arc: sOO"'TI in Annn:ure A. Illi wtl1l\$ the 
dt1aikd statIStics IQr the paired !-ItS!. 
" 
Forced expiratory volume in I second (FEV1) in % predicted 
There is a sign ificam improvement in FEV, 3momhs, 6 monlhs and 12 momhs after L VRS 
compared to the pn."Operalivc values (p< 0.05). After 4 years the mean value is still above 
baseline and in the h·\"Q patients with the louges! follow up there are still measured higher 
values of FE V I than preoperatively. Table 6 lind Figure 16 are demonslrating these results: 
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Forced vital capacity (l-'VC) in % predicted 
A similar trend is seen measuring the (or~d \'ital capaci ty. allhough it did oot rea~h 
SlastiSllcat signifi~an~c. The sqUUtl"S in Fil!urt 17 reprtsellL the mean values of FVC in 0/. 
predicted. Starting preoperatively at 65'-' predicted a steady improvement i~ noled un tillhe 
second yellt. where it reache~ 81°!. o(predicted . 
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TOI::allung capacil)' (TLC) and residual \'oluol(' (RV) in % predicted 
Unfortunately the follow up (or ll..C and R V was nOI complete duC' to inaeecs5IIbjlity of 
body p1ethysmogmphy. Six mOllIh.s aller L VRS the I'alues for onl y two patients could be 
dc lcrmincd and thcrc fo~ Figure I H and 19 only sho .... the means preopera tivc.) months. 12 
months and 18 months aller l VRS. The trend is \'bible. both TLC lind RV are dimmished 
aller I. VRS. "'hich could be cx~ted according to the liter~lurc, and are lncrca~jng at 18 
1»01111111 aguin. 
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Figure 18: Mean values for total lung capacity (TLC) 
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Figure19: Mean values for residual volume (RV) 
Nevertheless there is a significant decrease in residual volume (RV) 3 months ~ 12 months 
and 18 months postoperatively compared to the baseline values preoperatively (p< O.05)~ as 
shown in Table 7: 
31 
Paired Samples Test 
Pai red Differences 
95% Confidence 
Intenal of the 
Sid. SId. Error Difference Sig. 
MEtan DelAation MEtan Lower Upper t df (2-1aile~t 
Pair 1 Initial-3m 79.00 38.45 1923 17.81 140.19 4.109 3 
Pair 2 Initial-6m 49.50 3323 23.50 -249.10 348.10 2.106 1 
Pair 3 Initial-12m 67.60 52.75 23.59 2.11 133.09 2.866 4 
Pair 4 Initial -18m 82.50 6.36 4.50 25.32 139.68 18.333 1 
Pair 5 Initial- 24m 44.00 14.14 10.00 -83.06 171.06 4.400 1 
Table 7: Paired t-test (preop to follow up at 3m, 6m, 12m, 24m), significance is shown in the far right column 
Carbon monoxide diffusion capacity (TLCO) in % predicted 
The single breath method determining the carbon monoxide diffusion capacity was applied 
in nine patients preoperatively. The patient with the lowest value (22.88% of predicted) died 
a few hours after surgery in respiratory failure. 
We did not exclude patients with TLCO lower than 30% of predicted. 
The trend towards improvement of the diffusion capacity after L VRS is demonstrated in 
Figure 20: 
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Figure 20: Mean values carbon monoxide diffusion capacity (TLCO single breath method) 
32 
.026 
282 
.046 
.035 
.142 
6 min walk test 
The 6 min walk test could be perfonned on all ten patients preoperatively and is an easy test 
to determine effort tolerance. Figure 21 and Table 8 demonstrate the significant changes in 
the six minute walk test after L VRS and the lasting effect of L VRS concerning walking 
distance and indirectly dyspnea. 
,.."" 
..,""-
500 P [ [b 
400 
( 
3001 
I 
~ 200. 
m ~ 100J~ __ ~ ____ ~ __ ~ __ ~ ____ ~ __ __ 
1 
. . • • • N= 10 5 6 5 <4 
nital 3m 6m 12m 18m 
Figure 21: Mean values for the six minute walk test 
Pllred Simple. Te.t 
Paired Differences 
i 95% ConficienO!l Interval of the 
Std. Std. Error DifferenO!l 
Mean Deviation Mean Lov.er \..bper t df 
Mllf 1 IOllal- "m 
-2".60 130.16 ~.21 ·37~.21 -bO.99 -3.738 -4 
Pair 2 Inital- 6m -232.67 137.61 56.18 -377.08 -88.25 -4.141 
Pair 3 Inial-12m -145.60 54.30 24.28 -213.02 -78.18 . -5.996 
Pair 4 Inial-18m -52.50 75.44 37.72 -172.55 67.551 -1.392 
Pair 5 Inial-24m 
-25.00 28.28 20.00 -279.12 229.12 -1.250 
Table 8: Paired t-test 6 min walk (preop to follow up at 3m, 6m, 12m, 18m, 24m), sigificance is shown in the far right 
column 
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5 
4 
3 
1 
I 
Sig. 
(2-tailed) 
.U2U 
.009 
.004 
.258 
.430 
3.4. Costanalysis: 
A detailed list of all items is enclosed in Annexure B. The basis of this cost analysis are 
prices of the year 2000 in a state hospital reflecting the hospital stay of the patients 
undergoing L VRS with all costs covered (Table 9). 
The average amount spent for L VRS is approximately 30.000 Rand. 
Table 9: Costs for L VRS 
Patient 1 2 3 4 5 6 7 8 9 10 
KA VN MI MY VDB SCH NE TR SM SN 
ICUcosts 8292.00 8292.00 12438.00 16584.00 16584.00 4146.00 4146.00 4146.00 4146.00 2073.00* 
days 4 4 6 8 8 2 2 2 2 1 
Wardcosts 5628.00 1876.00 9849.00 3752.00 938.00 4690.00 4690.00 8911.00 3283.00 
days 12 4 2L 8 2 7 10 19 7 
Subtotal 13920.00 10188.00 22287.00 20336.00 17522.00 7429.00 8838.00 13057.00 7421.00 
Costsfor: 
preop consultation 149.00 149.00 149.00 149.00 149.00 149.00 149.00 149.00 149.00 149.00* 
Diagnostic tests 1952.80 2033.00 1563.70 2033.00 2033.00 2033.00 2046.20 2033.00 2033.00 2033.00* 
Procedures 3322.20 3322.20 5259.28 3322.20 3322.20 3322.20 3322.20 3322.20 3322.20 3487.48* 
ICU registrar 566.40 566.40 849.60 1132.80 1132.80 283.20 283.20 283.20 283.20141.60* 
thoracic surveon 298.00 298.00 298.00 298.00 149.00 298.00 298.00 298.00 298.00 298.00* 
Pulmonologlst 298.00 298.00 298.00 298.00 149.00 149.00 298.00 298.00 298.00 298.00* 
Physio 964.00 394.40 942.00 854.60 602.50 361.50 591.60 602.50 832.40 0.00 
Medication 474.60 566.75 798.76 343.75 289.02 179.93 145.76 228.25 160.53 53.78* 
Nutrition 131.34 92.84 265.75 375.79 n,84 55.58 264.40 128.20 74.69 425.38* 
Oxygen/Gas 465.74 461.52 297.20 164.16 385.04 334.80 323.46 416.16 261.88 330.58* 
Ventilation 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 354.00* 
Laboratory 916.22 904.25 1716.73 1955.61 1216.03 945.89 1007.88 1012.87 640.31 565.58* 
BIoodbank 99.00 99.00 99.00 99.00 99.00 99.00 99.00 99.00 99.00 770.00* 
Consumables 6961.47 6961.47 7679.44 7685.41 6888.64 6961.47 8888.99 5966.11 7653.81 6649.28* 
X-rays 584.90 537.00 898.60 941.10 845.30 675.30 494.50 669.90 223.30 90.40* 
Subtotal 17183.87 11883.83 21115.01 19652.42 17338.37 15847.87 18212.19 15507.10 18321.32 
Total costIpat. 31103.87 26851.83 43402.06 39988.42 34860.37 23271.87 27048.19 28584.10 23758.32 
• excluded from average 
These prices include the preoperative diagnostic tests routinely performed before L VRS, the 
hospital stay, the medication, the laboratory costs, the consumables and the doctors fees 
according to the scale of benefit values in the MASA guidelines. Costs are calculated 
accurately from the patients folders and range from 23276.87 - 43402.06 Rand. The highest 
costs (patient 3) were due to the need for a reoperation for a prolonged air leak. This caused 
higher costs for the procedures, the consumables and the hospital stay. The patient, who 
died, was excluded from the calculations. Table 9 shows the details. 
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Average 
30983.76 
1. Medical treatment scenario 1: 
Patient with severe emphysema on optimal medical treatment: 
Evaluation is based on the information in the folders of our 10 patients preoperative and 
information of experienced pulmonologists, who treat many of these emphysema patients. 
These patients are still working or doing their household, no hospital stays are required and 
they are managing with intermittent home oxygen. The costs are estimated for one year. 
Medication: 
Ventolin refill 
Atrovent refill 
Euphyllin ret tbl. bd 
Prednisone 10mg daily 
x 12: 
x24: 
700: 
1000: 
Nebulizer solution twice daily 1 ml 
ie. Berotec 20 ml x 36.5: 
Saline bags 200ml x 15: 
Beconase 50 ml aerosol x 2: 
(or Inflamide + Spacer 
AmoxillAugmentin tds (5days) x 4: 
Mistabron 
state tender 
95.52 
435.12 
79.31 
60.50 
320.47 
135.90 
20.04 
not available 
150.00 
not available 
wholesale 
260.76 
1498.80 
964.48 
124.67 
1326.05 
193.50 
249.92 
261.00 ) 
404.64 
60.19 
13.16 31.64 
Ill. 
'f ~ Influenza vaccination 
Subtotal: 1310.02 5114.65 
Home oxygen: 
L TDOT for 12-16h per day 7320.00 (State pat.) 
Physiotherapy: 
Percussion and breathing exercise x 20: 872.00 
Special motivation: 
Le. Nebulizer or home oxygen 56.10 
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Visits/Consultations: 
Physician x4: 299.90 
Pulmonologist x2: 290.30 
Diagnostic tests: 
Chest radiograph x3: 271.20 
Lungfunction test (limited) x2: 377.60 
Bloodgas x2: 89.20 
I Total: 10886.32 14690.95 
Medical treatment scenario 2: 
Patient with endstage emphysema: 
These patients are bedridden, fully oxygen dependant and cannot care for their own needs, 
nursing is required. Three of our patients were preoperatively in such a bad state, one patient 
post LVRS, who is still alive 4 years postop, also falls in this category. 
Medication: state tender wholesale 
Ventolin refill x 12: 95.52 260.76 
Berotec refill x 12: 134.76 630.30 
Euphyllin ret tbl. bd 700: 79.31 964.48 
Prednisone 10mg daily 1000: 60.50 124.67 
Nebulizer solution twice daily Iml 
i.e. Atrovent 20 ml x 36.5: 1291.61 1991.80 
Ventolin 20 ml x 36.5: 229.95 637.66 
Saline bags 200ml x 30: 271.80 387.00 
Beconase 50 ml aerosol x 10: 100.20 1249.60 
(or Inflamide + Spacer x 5: not available 1305.00 ) 
Cefuroxime 750 mg 8 hourly x4: 581.40 2529.60 
AmoxiVAugmentin tds (5days) x2: 75.00 202.32 
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Moduretic 25 mg daily x 365: 
Mistabron 
Influenza vaccination 
Vitamins tbl. daily x 365: 
Subtotal: 
Home oxygen: 
L TDOT for 12-16h per day 
Hospital stay: 
20 ward days/year 
4 ICU days/year 
Physiotherapy: 
Percussion and breathing exercise x 30: 
Visits/Consultations : 
Physician x4: 
Pulmonologist x2: 
in hospital x 12: 
I CU registrar x4: 
Diagnostic tests: 
Chest radiograph x6: 
Lungfunction test (limited) x4: 
Bloodgas x8: 
ECG x4: 
Laboratory 
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33.54 164.01 
not available 60.19 
13.16 31.64 
not available 23.64 
2966.75 9197.49 
7320.00 (State pat.) 
9380.00 
8292.00 
1308.00 
299.90 
290.30 
747.60 
566.40 
542.40 
755.20 
356.80 
127.50 
-1000.00 
HomeopatbyIPsychiatrist: 
Nursing: 
Excluding meals on wheels 
5 days homevisit (morning, lunch, evening) 
* not cost effective 
4 hours daily (7.00 - 13.00h) 
Total: 
Medical treatment scenario 3: 
Patient with good result after L VRS (f.e. second year): 
- 400.00 
( 67860.00* ) 
23504.00 
57856.85 64087.5 
The patient is fully independent, is exercising, does not need home oxygen, Dyspnea score II 
(Table 2) and is looked after by his general practitioner. 
Medication: state tender whole sale 
Ventolin refill x 12: 95.52 260.76 
Atrovent refill x 24: 435.12 1498.80 
Euphyllin ret tbl. bd 700: 79.31 964.48 
Prednisone 5mg daily 500: 30.25 62.34 
Amoxill Augmentin (5 days) x I: 37.50 101.16 
VisitsiConsultati ons: 
Physician x4: 299.90 
Diagnostic tests: 
Chest radiograph x2: 180.80 
Lungfunction test (limited) x2: 377.60 
I Total: 1536.00 3745.84 
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These three scenarios represent the cornerstones of the following estimations: 
The worst case scenario is reached in the end stage of the disease without or with L VRS. Our 
experience and others (47,65,86), as well as taking into account the natural history of severe 
emphysema (41) one can assume, that L VRS is shifting the time until this end stage is 
reached by 3-4 years, for some of the patients even longer. 
With medical therapy alone the estimated costs will develop as follows: 
First year second year third year fourth year fifth year Subtotal 
10886.32 22628.95 34371.58 46114.21 57856.85 171857.91 
14690.95* 27040.11* 39389.27* 51738.43* 64087.59* 196946.35* 
Once in this 5 year period the special investigations (fe. CT scan, alpha 1 anti-trypsin test, 
skin prick test, full lung functions etc.) have to be added, which brings us to an estimated 
cost over a five year period of: 
Total: 173 226.81 ( 198315.25 *) 
• calculation with whole sale prices for the outpatient medication 
A realistic outcome after L VRS is the following estimation, based on the mean costs of 
L VRS in our ten patients plus the yearly costs in the five year follow up period in a patient, 
who responded well to the operation, but follows the natural history parallel to the medical 
treatment alone, assuming that he is back to baseline after 3 years: 
First year second year third year fourth year fifth year 
30983.76 + 1408.00 1536.00 6211.16 10886.32 22628.95 
(11 m at home) 
30983.76 + 3433.69* 3745.84* 9218.40* 14690.95* 27040.11* 
(lIm at home) 
Total: 73654.19 ( 89112.75* ) 
With LVRS and reasonable response to the operation an estimated 100000.- Rand are saved 
in a 5 year period. In the following years the gap will decrease again due to the natural 
history of the disease. The most costsaving factor is the independency gained (Table 10) and 
the improved effort tolerance, nicely demonstrated in the 6 min walk test (Figure 21 ). 
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3.5. Quality of life: 
An overview of the well being of our nine patients is shown in Table 10. 
This infonnation was gained from the folders and notes at the follow up visits at GSH and 
from the pulmonologists or general practitioners involved in the follow up and from the 
patients themselves. 
Table 10: Summary of daily activities until the last follow up: 
Patient Follow up Well being 01 use Steroids 
.KA 12m Feels fine, is looking for a new job, N N 
Fully independent 
VN 12m Markedly increased ET, walks on the beach as long N N 
as she wants, moved from Pretoria to Durban, own 
shopping, fully independent 
MI 12m Back at work fulltime, walks her dogs every day, PRN Y 
full independence 
18m Still working, but decreased ET (50m), decline 
noted, mUltiple hospital stays, almost back to 
baseline 
SCH 12m Full independence, own shopping, ET well above N Y 
baseline 
24m Decline noted, depressed, on home oxygen Y Y 
Died 3 years post L VRS 
VDB 12m Full independence, 15 min cycling/day N N 
24m Doing well, still exercising N N 
36m Slow decline N N 
48m No change, still fully independent well above N N 
baseline 
MY 12m Full independence, walking on his own pace N Y 
24m Back to baseline Y Y 
4y Bedridden, nursing required 12 h, 02 continously refuses Y 
NE 12m Full independence, doing her household N Y 
24m Slow decline, ET decreasing, but well above Y Y 
baseline 
36m Wheelchair, physio 2x/week Y y 
Died 4 Y post L VRS 
SM 12m Full independence, own shopping, exercising N N 
3Omin/day 
24m Still good ET, doing her household N Y 
36m Functions above baseline,but moved to JHB and PRN Y 
feels a decline in high altitude environment 
TR 12m Full independence, regular exercise (gym) N Y 
24m Slow decline, still exercising, goes shopping, does N Y 
her household 
36m Gained weight!!, ET decreased, still doing her PRN Y 
household 
48m Stopped going to the gym PRN y 
60m Walking on her own pace, still independent PRN Y 
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Twn dilTerent quesuonnall'l:~ ~ou l d be complcK-d by 6 patients. They were administered by 
one interviewer in Jul)' 2000. r~!Tospecti \'l,' for the time before L VRS and I )'car aftcr L VRS. 
The i\'Ifdjcal Oll tcome Shldy Shun Forln J6 (I\ IOS SF .16); 
This inslrtUllC11t measures genel'D.l hcahh·rclatnl quality of life and is divided in 8 domaincs: 
PH - physical function 
2. RP - role limitatinn due: 10 ph)'sieal health 
3. BP - bodily pain 
4 GH = ge:ne ... 1 health 
.s. VT - walil)' 
6. SF - social fWK'tion 
7. , RE - role limi tation due: \0 emotional problems MH - mental h~alth 
The b.:st Kore is 100 and the worst scort' is O. A change nf20 points is regarded as 
significant . 
The mcan overall score in our 6 pa11en lS improwd fmm 28.3 proopernti\'e 10 70 .95 one: 
y~r poslOpcratiVl!. this and all indi.i dual oomDIn$ ue('])t bodil)' pain showed a significant 
difference in the quality o flife score: pre:. and postopcrath·c:Jy. as shown in Figure 22: 
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The ['hysical Component Score (PCS) and Mental Component Score (MCS) depicted above 
arc lite physical and menial summnrie.s for the SF-36. and arc displayed on whm's called a 
standardized "50- [0" sca[e. 
The mean score for Ihe general U.s. population For I'CS and MCS is .50, and Ihe standard 
deviation oflnose scores is [0. BOlh scores arc directly comparnb[c, and Ihe extcnt orthe 
IMindon of ~:ICh score from the mean is standardized in equivaknl standard dcviation units, 
Each [0 poim difference is equal \Q one standard dcvinlion. TIns ma~es Ihe interpretation of 
lhe l\.'$u[15 easier Prcopcrall\'C values arc PUI next to Ihe resuhs [ year after L VRS for each 
pallent (Figure 24). 
[n all pallenlS Ihe ['CS (mean 28) was preopcraiivc 2 or more standard deviations below Ihe 
genClllI U.S. I'opu[alion nnd improved I year afler l. VRS in average ! 2 points. still ranging 
below mean values, 
The Menla[ Component Score slarted in al'crnge 16 points below mean. bUI was in all 
pmicnls I1OOl'e Ihe mean of Ihe general U.S. populalion I )'ear after L VRS. 11 increased in 
alcroge 2) poinlll (> 2 SO), which demonstrales Ihe menta[ sirength and confidence these 
palients gained. 
Figure ~S shows the 8 different domaincs preoperatively (right) and I year Dfter l VRS 
(left ), only bod,ly pain did nOI change significantly. mainly because Ihe patients did nOI hD"t' 
a [01 of pilin preoperath'cly. n[[ other qualities changed drnmatical1y and reached 
significance (change > 20 points) . 
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This inSlrumenl is a dlscase specilk 20 item.ql,leslion nall1~. It mC35UTC'S symptolR~ in the 
are:I of; 
I D)·spnea (5 ql,leslions) 
2. Falli;uc(4) 
J. EmotIOnal function (7) 
4 MMlery(4) 
During $Clf·~ll-'CIN da)·lo-day IIClivUJd. Each dom;lln is scored on II SCllle of \-7 A change 
In 5COI'e 0(005 per item has been lISSOCiatcd With a minimally important difference In health· 
R'Ja\cd quailly ofhfe. a change of I IS nlOdemte and a change oflllO<l: than I is I IUflIe = 
signilicanl difTeft'11Ce (60). It takes 20 min to IKInunister 
FiKure 26 dlov.'S the mean scores in cxh domaine pro:op:ratheJy and J )taf after L VRS and 
the O\'l:raJi score. Tbe overall ~ changed (ronl 2.3 prcop to 5.6 one)ear after surgClj'. 
which is hii;hly sijnificanl, as Wl'ft' the chnnics in the domaincs. 
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4. DISCUSSION: 
With the revival of IJrantilllU1' 5 idea of multiple wedge resections for severe emphysema by 
Cooporr c\ al ill 1995 II illl'l:le number of small series, trials and publ iealions have flooded the 
medicallilcralure. As with c"cry "new" IIXhnique it took II few years unlil the cornerstones 
of the method had been established. Most of the sdection criteria and surgical \e<:hniques nrc 
now sl:ind:lnliZC'd within certam limns. The main short rome is tha:. no big prospective. 
IlIIl<Io-rni$ed 5tud) lias been completed Two major studies are underway but still in lhelr 
enrolment pbasl:, one IS the NI:.-rr- Nallonal Emplt)'5ClTl1l Treatment Tna! (125) and Ihe 
second I~ the CI. VR·Sludy - CanaduUl Lung Volume Reduction Siudy (87.88). One has \0 
rdy on ~mall studies with short- and median folio,,·ups 
(13,34,39,47.81.85,107. 108,1 12. 1 13,119). 
Due 10 remi t ted mallpo .. -er an.! budget constraints ill the moment in South Africa we can 
only anru}se our data retrospectively and investigilk. whether we can keep up wllh 
in tenwiOllal Sll1Ildard:s. Especially for South Africa il i5 of utmost importllncc 10 In' estignte 
not only \he technical feD.ljibi lityand phY5ioiogicai OUlcome after I. VRS. but also evaluate 
the eosts nmlthe bellt:fits for the paliC1lts in terms of qunlity orlirc. 
The presented data can be: looked at from difft:rcnt angles, We arc aware. that it i~ a small 
serics with gaps in the follow up and it is a rctroSpect;'·c analysis, Neverthtless a few 
imerest ing poinls need 10 be emphnsin:d: 
• Thc chokc of opemting via a mediarutemotomy on both lungs and the usc ofGRF (gelatin. 
resorcinol.fonnnidchydelgiutntaidehydc) glut': to prevent major &lr Jcllk.! seem to ha\ e 
I'l:sulted 11\ p fairly low and acceptable morbidity (Table J). Only Ollt patient ,",en! back to 
theatre !)e(:ause of a prolonged air lellk.. all olhcr p.,tients "stopped bubhling" in less than 14 
days and could leave hospital without il bollie or a Heimh~h valve. 
Postoperative pam and therefore respinuory function are not as silif\ificantJy impaired as 
with a thoracotomy and the target areas bilntcrally can be easily reached. 
We can staple the lung in such D way, thal it will fit .... ell into the thomck cage PJld \Ie try 
not to staple away triangles or amputate the apex, 
II has to be emphasi:a"'<llhatthe utmost care is necessary to use the ORF glue only on the 
stapling device and the stapled edge. avoiding contact with lung lissue or other 5Iructul'Cll. 
The loxic componenl foftllalinc: could othern'i5e cause necrosis (9.129), 
I'rrsonal comml1l1icalion .... ith some o"crseas thoracic !l1fgCOl1S draw the attention to the 
facl. IhN prolonged air leah are a major problem, I10t only ..... 'Ih lhe [aser technique (73) but 
also \1 1th stapling these emphysematous lungs. Tnt: Bromplon group lherefore docs not 
hl:sitate to send their patients home with a Heimlich valve. ac~epling a comorbidity in these 
patients. The use ofGRF glue in our experience worked well. il is cheaper than bovine 
pericastlium or- I'TFE fellS and C3S} applicable. 
A previous review (88) reponed morbidlly and complications afte r [. VRS as high as the 
following figl11'e5: prolonged air leaks (4()'55%), tracheobronchitis (46"6). poSlopcrali \'c 
pneumonia ([ 7·22-.4). prolonged postoperali>-e IIlC'ChanieaJ \'C1Ililalion (\3. [,.4). 
arrhythmia (21~.), reoperation for au leaks (10",.). reoperalon for bleeding (5~). 
pneulllothoraces (SO"/o) and postoperat.i,·e m)'ocanltal infllTClion (0.9-..-). 
• Strict adherence to the inclusion and exclusion cmena resulted in a limited number of 
patients offered L VRS. EspeciaJly in South Afri~ with financial limitations and ongoing 
.. 
budget cuts this operation is offered only to a small group of patients, who are already 
imposing major costs on the community. This selection process will prohibit inflational use 
of this technique and, as pointed out in later sections, it is cost effective at least over the next 
five years and provides impressive and valuable improvements quality oflife. 
A 30 day mortality of 10 % , in our study one patient, is compatible with international 
standards, 0-20% reported in various series (8,33,47,82,119). One interesting observation 
from the recent prospective randomised study from Brompton (47) is that they changed their 
exclusion criteria regarding the carbon monoxide diffusion capacity and excluded patients 
with values lower than 30 % predicted. The reason was that they had 5 deaths out of the first 
15 patients, all of them with values lower than 30 % of predicted. The patient, who died in 
our group, had the lowest TLCO value of all with 22.88% of predicted. 
This leads to the question: Who benefits the most? 
Inhomogeneous distribution of emphysema and clear target areas makes it easier for the sur-
geon to resect most affected areas. Demarcation is facilitated by preoxygenation with 100 % 
oxygen and consequently collapsing the lung. Areas with severe gas trapping stay pink 
longer and can be identified as target areas. 
Four of our patients had a homogenous pattern, confirmed by both high resolution CT -scan 
and a perfusion scan, but two of them are doing exceptionally well, one died 4 years post 
L VRS and one is back to baseline after 18 months. 
As demonstrated by Gelb et al (48) it seems, that in each study there are some patients, who 
do not show the expected benefit from L VRS, he calls them "short term-responders", others 
would say "non-responders". In our study there is at least one patient, who has returned to 
her preoperative status 18 months postoperatively, probably due to a combination oflow 
preoperative lung function and a homogenous pattern of emphysema. She was the only 
patient, who was unable to perform a bodyplethysmography preoperative, so we have no 
values for residual volumes or diffusion capacity before L VRS. 
Alpha 1 anti-trypsin deficiency is not regarded as a contraindication per se, one patient is 
now bedridden 5 years after L VRS, the other one is doing very well 4 years after L VRS. 
The question, why some people have an impressive and long-lasting benefit as opposed to 
others, who are deteriorating soon after L VRS, remains unanswered. 
• One central issue in the assessment of any procedure designed to improve function in 
patients with COPD is the dyspnea. Dyspnea is a subjective sensation and the severity may 
or may not correlate with physiological measurements (78). 
Five parameters reflect the degree of dyspnea: 
- the dyspnea score 
- the quality of life assessment CRQ and PH in the SF-36 
- performance was evaluated by the 6 min walk test 
- the use of home oxygen as an indirect reflection on dyspnea (Table 10) 
- physiological evaluation by spirometry and plethysmography 
Our data clearly showed an improvement of all these parameters for the first 12 months, 
most patients had a measurable benefit for more than 2 years. 
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The 6 minute walk test is a very reliable indicator of effort tolerance. It was significantly 
improved up to 24 months postoperative. This reflects the findings of Geddes et al (47) in 
their prospective randomised study. 
It was shown impressively, that the medical ann continues to follow the expected 
deterioration according to the natural history of severe emphysema (Figure 28). The surgical 
arm follows parallel on an improVed level, hitting the baseline (=preoperative values) after 
approximately 2 years and keeps on deteriorating in the next few years parallel to the 
medical arm. 
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Figure 28: Survival in patients diaposcd with chronic obstructive pulmonary disease who bave a forced expiratory 
volume in I second less than 3OO"" of predicted (9S) 
Probably the best reflection of the natural history of patients with severe emphysema is 
gained from a report from Meyers et al.(86). He followed up 22 patients, who were selected 
for L VRS, but were denied the operation by Medicare. He compared these patients with the 
ones, who underwent L VRS. He showed an actuarial survival after 36 months of 64% in the 
patients denied the operation and a 83% survival for patients undergone L VRS. He also 
showed a significant improvement in FEV I after 12 and 24 months, as well as sustained 
improvements in the frequency of oxygen use at rest and at exercise, relief of dyspnea and a 
decrease in steroid requirements. 
Considering all above mentioned points, our spirometry values showed the least reliable 
correlation between subjective relief from dyspnea and measurable improvements of lung 
functions. This was noted by other authors before (13,33,48). 
• A second central issue is the question: Bow eost effective is this treatment? 
The techniques of economic evaluation offer a systematic framework for identifying, 
measuring and valuing the resource input (costs) to a health care program (Le. a new drug or 
surgical procedure) and the health benefits associated with the intervention. Especially in 
view of the situation in America and the precedence, that Medicare does not pay for L VRS 
so 
until beneficial effects are proven (54), one should look at the costs, these patients 
accumulate over the years with their severe disability. 
Figure 28 demonstrates the natural history of severe COPD. According to our findings and 
that of many other small series (47,48,113), five years would be a realistic time interval to 
look at. The costs of medical treatment alone and costs of L VRS plus medical treatment 
required for the following 5 years are calculated at the endpoints of year 1 and year 5 and 
extrapolated in between. Knowing the natural history (44) and the requirements with 
progression of the disease (hospital stays, medication, loss of independence etc.) this is a fair 
assumption. 
A longer period is unrealistic, because many patients would drop out because of death. 
According to Bergner 70-80% of these patients will be dead within 5 years (15). 
An economic evaluation does look not only at the costs, but also analyses the effects and 
benefits gained by a treatment or procedure. A simplification of this is shown in Table 11: 
Table 11: Dominance and trade offs in economic evaluation (98) 
More effective Less effective 
More costly Trade off Dominance to reject 
Less costly Dominance to accept Trade off 
Ifa new intervention is demonstrated to be both less costly and more (or equally) effective, 
then there would be a dominance (= "win-win" situation) to adopt the new therapy, which 
is the case in our study for L VRS. It clearly demonstrated, that over a five year period a 
substantial amount in the region of 100 000 - 110 000 Rand can be saved, if patients 
undergo LVRS. 
All economic evaluations distinguish between direct cost and indirect costs. Direct costs are 
the value of resources consumed in delivering care (i.e. medication, hospital costs etc.). 
Indirect costs are the value of lost or gained production due to the patient's inability or 
ability to work as a consequence of the disease or treatment. 
In our study we neglected these indirect costs from the societal viewpoint, because our 
patients were either pensioners, did not work before or after L VRS or did work before and 
after L VRS. So there was no change in indirect costs. 
If there is evidence, that health outcome from a new therapy is equivalent or better than the 
comparison therapy, then it is legitimate to consider costs only (98). Cost analysis is not 
only including the costs of the procedure (Table 9), but also costs over the following years 
as outpatients and if necessary inpatients. 
A cost utility study looks at costs plus quality of life gained. The cost utility could not be 
assessed accurately, because the quality ofHfe score, which allows to measure quality 
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adjusted life years (= QAL V's) was not made available to us. But this leads to the third 
central issue: 
• The question to answer is: Do patients undergone L VRS gain quality of life and if yes, 
for how long? 
In bigger, randomised studies usually one general health index (i.e. SF-36, Nottingham 
Health Profile) and one or two disease specific instruments are used to assess quality of life. 
Both tests used in our study are proven to test quality of life and are sensitive and specific to 
changes in the respiratory status. They have been used for COPD and L VRS in previous 
studies. They are easily administered, reliable and reproducible (49,50,69,76,77,80,104, 
120,122,127,132,134). 
Unfortunately the third test, the Health Utility Index 2/3, a 40 item questionnaire was 
assessed, but the algorithm and therefore the evaluation of outcomes is not freely available 
and subject to royalties in the United States and Canada. 
HUI 2/3 would have been the only test, which allows the assessment of deaths during the 
follow up period, integrates the quality of life and survival in a single outcome (Quality of 
life years=QALY's) and could be used in the economic evaluation for cost utility and cost 
effectiveness (42). 
A significant difference was shown between quality of life preoperative and 1 year 
postoperative, the patients were mobile on basic medication, off home oxygen and gained an 
enormous amount of independency. Both the physical scores and the mental scores 
improved significant. The mental health score in the SF-36 (MHS) was lying over that of the 
general U.S.population. 
Unfortunately four patients either died before the evaluation or were not willing to complete 
the questionnaire, but from the existing notes by the Respiratory Clinic their outcome after 
one year would not have been different concerning quality of life (Table 10). 
In 4 out of 9 patients a steady decline was noted after 2 years, following the natural history 
of COPD, all nine patient's records confirm a marked improvement of quality of life one 
year post surgery. 
Even taken into consideration that the questionnaires were applied retrospectively, the 
consistency of the results and the clear differences shown in all scores (Figures 22-27) 
emphasize, that this part of the study shows a clear advantage for LVRS. 
The patients could remember clearly and described in detail, what their condition was 
preoperatively and one year post L VRS, which is reflected in the two quality of life scores. 
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CONCLUSIONS: 
• We have proven, that L VRS is a safe and cost effective procedure for carefully 
selected patients with severe emphysema. These patients gained physical and mental 
strength, evaluated in two quality of life scores. 
• Our results are in line with international standards, and our hypothesis is proven to 
be valid. 
• We will be able to participate in the prospective randomised multicenter study from 
Canada, which will further decrease the impact on our own health budget. 
Only a big study like this can give conclusive proof and answers to unresolved 
questions around L VRS. 
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Annexure A: 
FEY 1 in % predicted 
Pt. Nr. preop 3m 6m 12m 18m 24m 36m 48m 60m 
1 13 17 17 20 
2 21 28 26 23 
3 16 39 37 22 23 
4 29 32 32 32 24 38 
5 21 25 28 24 26 27 24 25 
6 18 17 15 13 15 
7 17 24 25 21 
8 27 48 39 41 38 26 38 34 
9 19 25 20 24 19 17 17 
10 16 
Mean 20 28 2S 26 24 24 22 
Number 10 9 8 7 6 6 4 
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Std. Std. Error 
Mean N Deviation Mean 
t-'ar IlIU:lI 2U.ll ij O.M 1.71 
1 3m 28.33 9 10.07 3.36 
Psi" nital 19.25 8 4.74 1.68 
2 6m 25.00 8 7.48 2.65 
Pair nital 20.86 7 5.67 2.14 
3 12m 26.29 7 6.75 2.55 
Psi" nital 21.67 6 5.20 2.12 
4 18m 24.33 6 9.37 3.83 
Psi" nital 21.83 6 5.00 2.04 
5 24m 24.33 6 11.83 4.83 
Pai' nital 21.00 4 4.32 2.16 
6 33m 22.00 4 3.92 1.96 
Pair nital 24.00 2 4.24 3.00 
7 4Bm 31.50 2 9.19 6.50 
Pairecl Samples Correlations 
N ! Correlation Sig. 
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Pair 2 nital& em 8 .402 .323 
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Pt.Nr. preop 3m 6m 12m 18m 24m 36m 48m 60m 
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Pt.Nr. preop 3m 6m 12m 18m 24m 36m 48m 60m 
1 126 97 104 114 
2 160 144 
3 131 151 
4 143 134 
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6 111 
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RV in % predicted 
Pt.Nr. preop 3m 6m 12m 18m 24m 36m 48m 60m 
1 280 188 206 245 
2 301 310 
3 185 354 
4 286 181 
5 309 213 217 222 237 
6 209 
7 356 334 330 
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9 296 184 263 
10 236 
Mean 280 220 162 247 
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a. The correlation and t camot be computed because the sum 
of caseweights is less than or equal to 1. 
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Pt.Nr. preop 3m 6m 12m 18m 24m 36m 48m 60m 
1 43 43 53 
2 36 43 31 
3 51 19 
4 28 53 75 58 
5 50 41 57 52 54 
6 27 26 
7 32 33 37 
8 51 69 71 68 51 
9 25 28 29 26 36 
10 23 
Mean 35 32 52 49 43 
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6 min walk test 
Pt.Nr. preop 3m 6m 12m 18m 24m 36m 48m 60m 
1 358 447 440 420 
2 360 480 520 
3 70 415 50 
4 246 625 650 
5 385 520 520 525 525 
6 277 
7 75 410 390 
8 325 475 536 415 370 360 
9 350 480 510 350 355 
10 245 
Mean 269 495 476 501 335 
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5 24m 362.50 I 2 10.61 7.50 
Pair nital 385.00 18 
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7 4Bm 360.00 18 
a. The correlation and t camot be computed because the sum 
of caseweights is less than or equal to 1. 
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Annexure B 
Detailed Listing of all costs 
ITEM 
Laboratory 
Microbiology: Urine or sputum microscopy 
culture 
Bloodculture 
HIV - Elisa 
Haematology: FBC + Diff 
FBC 
INR 
ptt 
bloodgas 
Chemistry: CEUG 
AST 
ALT 
Albumin 
Total protein 
Bilirubin 
AP 
alpha 1 anti-trypsin 
emergency chemistry and haematology: after hours 
Transfusion: group and screen 
crossmatch 
Red pack cells 
Whole blood 
FFP 
Diagnostic Tests: 
Limited PFT (FEV1/FVC) first visit 
consequent visit 
Full PFT (FEV1/FVC + Body box) 
Transfer factor 
6 min walk test 
va scan 
HRCTscan 
2000 COST PER UNIT 
24.30 
31.20 
68.80 
65.80 
63.10 
52.00 
29.70 
29.00 
44.60 
17.92 
26.73 
26.73 
15.39 
15.39 
23.61 
25.64 
35.60 
50% more after hours 
99.00 
170.00 
300.00 
339.00 
277.00 
236.00 
141.60 
188.80 
113.30 
76.30 
499.80 
941.70 
CXR 1 view 
2 views 90.40 
ECG 42.50 
Cardiac echo + colour doppler 217.50 
Skin prick test 13.20 
Medication: 
Antibiotics: Kefzol 1 9 iv 5.73 
Clindamycin 600 mg iv 21.50 
Cefuroxime 750 mg iv 9.69 
Gentamycin 240 mg iv 6.72 
Penicillin 5 mill iv 4.07 
Flagyl 500mg iv 5.52 
Flagyl 400mg po tds 0.18 
Erythromycin 250 mg po tds 1.16 
Bactrim 2 tbl bd 0.25 
Amoxycillin 250 mg po tds 0.34 
Augmentin 375mg po tds 7.16 
Flucloxacillin 500 mg qd 3.37 
Analgesia: Morphin 20 mg po (500 ml) 20.00 
Morphin 10 mg iv amp 0.83 
Morphin 15 mg iv amp 0.86 
Voltaren 25 mg po (20 tbl.) 0.84 
Voltaren 75 mg im 0.60 
Doxyphene po (100 capsules) 32.05 
Fentanyl 2ml 4.62 
Ketarolac 10mg iv amp 8.50 
Brufen 400mg (100 tbl.) 9.05 
Valoron 50 mg (20 caps) 28.50 
Panadeine (20 tbl.) 2.30 
Epidural: Bupivacain 0.5% 10 ml amp 7.58 
Bupivacain 0.5% 5 ml amp 3.37 
Lignocaine 2% 5ml iv 0.95 
Pancuronium 2 ml 5.67 
Suxamethonium 2 ml 0.98 
Vecuronium 4 mg (1amp) 14.99 
Neostigmin 0.92 
Etomidate 10 ml 23.03 
Propofol 20 ml 51.84 
Thiopentone 0.5 9 7.01 
Adrenalin iv 1 mglml 1.14 
Atropin iv 0.5mg 0.59 
Glycopyrrolate 2ml 1.55 
Naloxon iv amp 
Calciumgluconate iv amp 
KClivamp 
Ephedrine 50mg/ml 
Solumedrol 500mg 
Hydrocortison 100 mg iv amp 
Prednisone 5mg po (100 tbl.) 
Maxalon iv amp 
Maxalon po (50Otbl.) 
Aterax 25mg po (100 tbl.) 
Serepax 10 mg po (250 tbl.) 
Calciparin 5000 I.U. sc 
Heparin 5000lUlmi vial 
Aminophyllin iv amp 
Euphyllin ret po 250 mg (100 tbl.) 
Atrovent aerosol 
nebulizer (x 60) 
Berotec aerosol 
nebulizer (x 60) 
Ventolin aerosol 
nebulizer (x 60) 
po 2 mg (40 caps.) 
po 4+A291 mg (60 caps.) 
Beconase 50 mg aerosol 
Metamucil 250g 
Consumables for the operation: 
TA 90 stapler 
GRFGlue 
Steridrape 
Gloves 
Gown 
Diathermy plate 
Sutures 1 Nylon 
1 PDS 
2-0 Vicryl 
3-0 Vicryl 
Sternal wires 
bulb syringe 
Blades 
Swabs: Abdominal swabs 
Ratex 
Blue cleaning swabs 
Suction tubing 
Urine catheter (silastic) 
4.24 
2.03 
0.83 
7.80 
44.90 
4.02 
6.05 
1.03 
11.80 
60.57 
8.37 
5.82 
5.09 
0.73 
11.33 
18.13 
106.16 
11.23 
26.34 
7.96 
18.90 
20.90 
27.94 
10.02 
21.30 
963.30 
1019.70 
34.97 
14.46 
34.63 
7.19 
4.49 
25.30 
6.54 
5.42 
119.69 
15.16 
0.53 
20.03 
2.25 
2.18 
11.43 
9.63 
Urine meter bag 
Chest drain 
Tubing 
Dressing big 
Dressing small 
Saline por bottle 
Anaesthetics: 
Mask +Filter 
Double lumen tube (Bronchocath) left 
Double lumen tube (Bronchocath) right 
CVP double lumen 
Percutanous CVP+sheat 
Swan-Ganz cath. 
Epidural minipack 
guidewire 25 cm 
cannula 
Syringe2ml 
Syringe 5ml 
Syringe 10ml 
Syringe 20ml 
Needles 
3-way tap 
Airway 
Nasogastric tube + bag 
ECG electrode 
Tegaderm large 
Yankauwer suction 
iv administration set 15 dropper 
Transducer kit 
extension line 
Volatile gases: 
Halothane per minute 
Forane 
Oxygen 
Consumables ICU/ward per day 
Infusion: NACI 11 
NaCI 200 ml 
NaCI 10 ml 
HAES steril 
Plasmalyte B 200ml 
GMS 11 
Maintelyte 11 
Ringers Lactate 11 
Haemacel 500 ml 
Dextrose 5% 11 
Dextrose/Saline 11 
Rehydration 11 
Water 10 ml 
58.96 
15.80 
6.99 
3.21 
1.97 
8.34 
28.90 
317.07 
1041.01 
226.95 
154.12 
724.40 
70.06 
41.37 
2.89 
0.39 
0.56 
0.72 
1.12 
0.21 
2.69 
1.27 
10.41 
1.16 
6.63 
6.92 
3.17 
296.82 
5.36 
0.59 
2.69 
1.58 
10.00 
10.77 
9.06 
0.83 
61.56 
14.01 
9.47 
11.84 
10.67 
14.00 
7.98 
11.52 
11.32 
0.47 
Water 20 ml 
Infusion set: 15 dropper 
bloodset 
bloodset high capacity 
Dressing Tegaderm large 
Respiratory Therapy: 
Ventilation in ICU first day 
subsequent day 
02 Therapy one day 511 min 
Nutrition/Hyperalimentation per day 
Consultations: 
Thoracic Surgeon first visit 
consequent 
in hospital 
Pulmonologist first visit 
consequent 
in hospital 
Anesthesia pre op 
ICU registrar per day 
General practitioner first visit 
consequent 
home visit 
home visit emergency 
one off fee for consultations in hospital/day 
Writing of special motivation (f.e. home oxygen) 
Procedures: 
BronChoscopy Surgeon/Physician 
Anaethetist 
Bullectomy bilateral via medianstemotomy (1184) 
Surgeon 
ASsistant (20%) 
Anaethetist 
Anaethetist Assistant (66%) 
Wedge resection Surgeon 
Assistant (20%)+A53 
Anaethetist 
Anaethetist Assistant (66%) 
1.02 
3.17 
4.49 
7.70 
6.63 
354.00 
236.00 
7.68 
70.80 
162.00 
105.90 
62.30 
168.20 
122.10 
62.30 
99.70 
141.60 
75.50 
74.80 
113.20 
163.50 
149.00 
56.10 
306.80 
142.50 
2067.40 
413.40 
261.30 
174.20 
1722.80 
344.56 
261.30 
174.20 
Repeat thoracotomy Surgeon 
Anaethetist 
Open lung biopsy Surgeon 
Anaethetist 
Arterial line insertion 
Epidural cath. Insertion 
CVP line insertion via peripheral vein 
CVP line insertion via central vein 
Swan Ganz cath. Insertion 
PCA pump supervision (once off charge) 
Physiotherapy and Rehabilitation: 
Rehabilitation program Iday 
Chest physio percussion 
breathing exercise 
nebulization 
Hospital stay overheads 
ward per day 
ICU per day 
Outpatient treatment: 
Medication: 
Antibiotics: 
AmoxillAugmentin (5 days course) 
Cefuroxime (5 days course) 
Erythromycin (5 days course) 
Bactrim 2 tbl bd (5 days course) 
Aerosols: 
Others: 
Atrovent aerosol refill 
nebulizer (20ml) 
Beconase 50 mg aerosol 
Berotec aerosol refill 
nebulizer (20ml) 
Ventolin aerosol refill 
nebulizer (20ml) 
Inflamide + Spacer 
Prednisone 5 mg (1000 tbl) 
Euphyllin ret. tbl. (60) 
Moduretic 25 mg (100 tbl) 
Influenza vaccination 
Multi vitamins (30 tbl) 
Mistabron 
1652.00 
285.00 
542.80 
261.30 
118.00 
169.90 
47.20 
118.00 
236.00 
141.60 
48.20 
21.90 
21.90 
32.90 
469.00 
2073.00 
State tenderlwhole sale 
37.50 I 101.60 
145.35 / 632.40 
5.81 / 26.48 
1.25 / 10.04 
18.13 / 62.45 
35.39 / 54.57 
10.02 / 124.96 
11.23 / 52.55 
8.78 / 36.33 
7.96 / 21.73 
6.30 I 17.47 
not available I 261.00 
60.50 / 124.67 
6.80 /82.67 
9.19 I 44.93 
13.16 I 31.64 
not available / 1.97 
not available I 60.19 
Oxygen therapy: 
concentrator vital air medical aid pat./month 
concentrator vital air state patJmonth 
Cylinder 2 kg lasts 4-6 h on 5Vmin 
Cylinder 4.9 kg lasts 12-15 h on 5Vmin 
Cylinder 9.7 kg lasts 24-30 h on 5mllmin 
Rental equipment/month 
General practitioner 
General practitioner home visit 
Psychologist 
Physiotherapy 
Occupational therapist visit at home 
at the hospital incl. Transport! session 
Home care: 
Nurse full time 12 h shift 
Sunday 
part time! per hour 
Sunday 
one home visit 
Sunday 
• 
695.00 
610.00 
107.13 
169.00 
263.12 
105.00 
75.50 
113.20 
168.20 
43.60 
50.00 
41.00 
271.20 
406.80 
22.60 
33.90 
87.00 
130.50 
Annexure C: 
OA.RO SF-J6. BOOKLET FOR~( - P .. ')"CE ONE OF F(VE 
I THE IIOS 38-ITEII SHORT-FORII HEALnt SURVEY (SF-38) , 
lNSTRucnoNS: This survey asks for your views about your health. This information 
wi help keep track of hOw you feel and how wei you we able to do your usual activities. 
Answer every question by markfng the MSWW as incIcated. If you are unsure about how 
to .-.swer a question. please give the best answw you can. 
1. In general, would you say your health is: 
(circle one) 
Exc:ellent ....................................... '"' • . . . • • .. . • " 1 
Very good ............... " ............................ 2 
Good .................................... " •..•.• 3 
Fair ........................................ " ..••. 4 
Poer •..• " ............... " ........................... 5 
2. Compared to 00. year ago. how would you rate your health in general I9J{? 
(circfe one) 
Much better now than one year ago ...•................ 1 
Somewnat better now than one ye8r agu ................. 2 
About the same as one year ago . . . • • . . . . . . . . . . . • . . . . . . 3 
Somewhat worse now Ihan one year ago ••...•........... 4 
Much worse now than one year ago .................... 5 
eo.. .... r • ttll uos TftIII. IN:. 
M"~, 1 
STANDARD !if-JOt BOOKLET fOR:" - PACE TWO Of F'[VE 
3. The folJowing items are about activities you might do during a typical day. Does 
your health now limit yqu in these activities? If so. how much? 
(circle one number on each line) 
Vea, Ves, No, Not 
ACTMnES Umlted Umltec:t Umlted 
A Lot A UttIe At All 
a. Vlgorou. actIVItIes. such as ~t lifting 
heavy objects. participating in strenuous 1 2 3 
sportS 
b. Moderat. activities, such as moving a 
table, pushing a vacwm cleaner, bowling, 1 2 3 
or playing golf 
c. Utting or carrying groceries 1 2 3 
d. Climbing sev.ral flights of stairs 1 2 3 
e. Climbing on. fright of stairs 1 2 3 
f. Bending, kneeling, or stooping 1 2 3 
g. Walking more than a mile 1 2 3 
h. Walking sev.ral blocks 1 2 3 
i. Walking one block 1 2 3 
j. Bathing or dressing yourself 1 2 3 
4. During the OMt~St have you had any of the following problems with your work 
or other raguJa} daily activities as , "suit qt vgur phyIiQ!J """,,? 
(circle one number on each line) 
YES ·NO 
a. Cut down on the amount 0' time you spent on 1 2 
work or other activities 
b. Accomplished less than you would like 1 2 
c. Were limited in the kind of work or other , 2 
activities 
. 
d. Had difficulty performing the work or other 1 2 
activities (for example. it took extra effort) 
rANOARO SF·J6, BOOKLET FOR~( - PACE THR,EE OF FeVE 
~ 
5. o...tng the rmt (nllsl, have you had My of the following problems with your wctk 
Of' Other tfifP8/ daly IICtMIes •• ,.,« of any tmpIIgnII prgbIIms (such as feeling 
depfessed Of' anxious)? . 
(circle one number on each line) 
YES NO 
a. Cut down the amount of time you spent on work Of' other 1 2 
IICtMIes 
b. AccompIIIIIed'_ ttWI you woeAd Ice 1 2 
c. Dfdn"t do work or other 8CIiviIies as carefUlly as usual 1 2 
" 8. During the pee!' WIlks, to what extent has your physical health or emotional problems intetfered 'WIth your normal social actMIies with family, friends. neighbors, 
or groups? 
(circle one) 
Not at all ................................................. 1 
Slightty .................................................................... 2 
Moderately ••.••••.•••••••••••••.••••••••.......• 3 
Quite a bit • . • • • . • . . • • • . . . • • • • , • • . • . . . . , . • . . . . , . . . 4 
Extremely ......................................, 5 
7. How much bgdIv pain hIM you had during the~? 
(circle one) 
None .• , •• ' ..•.••.•..... , ", •.••••••••. , .•........ ; 
Very mild ' .•.•..•.•.. , ..•...•.•.•...............• 2 
Mild ......................•..................... 3 
Moderate ...............•........................ 4 
Severe ..•...............•.. '0' 0 •••••••••••••••••• 5 
Very severe .•. . . . . • • . • . • . • • • • . • . . . . . • . • . . . . . . . . . . 6 
CoIi.JItN • twa MOS r""" InC. 
............. 3 
TANDARO SF- 36. BOOKLET FOR~( - PACE FOUR OF FrVE 
} 
8. During the oast~geks, how much did .QIiQ interfere with your normal work 
Oncluding both outside the home 8'1d -housework)? 
)-
(cirde one) 
Not at all • • • . . . . . • • . • . . .' • • • • . . . . . . . • . '. . . . . . . . . . . . 1 
A little bit . • • . • . . . . . . . • . • . . • . . • . . . . . . . . • . . . . . . . . . . 2 
Moderately ...•...••..........•.................. 3 
Quite a bit . . . . . . . . . . • • • . . . • . . . . . . . . . . . . . . . . . . . . . . 4 
Extremefy ••••••••.••••••••••••.••••..••.•••.•••• 5 
9. These questions are about how you feel and how things have been with you during 
the past ¥wetks· For each questiOn, please give the one answer that ~~ A 
closest t6 the way you have bean feeling. How much of the tim, during the cr 
weeks -
(circle one number on each line) 
AGooc:I A 
All Moat Bit of Soma UttIa None 
Oftha ofUla tha oftha oftha oftha 
Tlme nme Tlma Tlma nma Tlme 
a. Did you feel full of pep? 1 2 3 4 5 6 
b. Have you bean a very 1 2 3 4 5 6 
nervous person? 
c. Have you felt so down 
in the dumps that 1 2 3 4 5 6 
nothing could cheer 
you up? 
d. Have you felt calm and 1 2 3 4 5 S 
peaceful? . 
e. Did you have a lot of 1 2 3 4 5 6 
anergy? 
f. Have you fait l' 2 3 4 5 6 
downhearted and blue? 
g. Did you feel worn out? 1 2 3 4 5 6 
h. Have you been a happy 1 2 3 . 4 5 6 
person? 
i. Did you tea tired? 1 2 3 4 5 6 
"DARD SF-J6. BOOKLET FORM - PAGE FIVE OF FIVE 
10. During the ~ how much Of the time has your phvIjc!!I buI!!J or 
emgtiona! ir1tIft8red with your social activities Oik8 visiting with friends, 
relatives. etc.)? 
Carde one) 
All of d1e ~ ............................................................... 1 
Most of tI1e tin1e ...................................................... 2 
SOIrI8 of tI1e time ................................................. 3 . 
A little of t:t1e time ......................................................... 4 
None of ttl. time ...............4o................................. 5 
11. How TRUE or FALSE is .a:n of the foRewing statements for yOlf! 
(cirde one number on each line) 
DefInitely Mostly Don't Mostly Definitely 
True True Know Fa'se False 
a. • seem to get sick a 
litde easier than ·1 2 3 4 5 
other people 
b. I am as healthy as 1 2 3 4 5 
anybody I know 
c. I expect my heaith to 1 2 3 4 5 
get worse 
d. My health is 1 2 3 4 5 
exceOent 
5 
CHRONIC RESPIRATORY INDEX OUESTIONNAIRE 
First Administration, 7 Point Scale 
INTERVIEiER FORM 
This questionnaire is designed to find out how you have been 
feeling during the last 2 weeks. You'will be asked about how short 
of breath you have been, how tired you have been feeling and how 
your mood has been. . 
1. I would like you to think of the activities that you have 
done during the last 2 weeks that have aade you feel 
short of breath. These should be activities which you do 
frequently and which are iaportant in your day-to-day 
life. Please list as many activities as you can that you 
have done during the last 2 weets that have aade you feel 
short of breath. 
[CIRCLE TO HUKBER ON THE AHSiD. SUET LIST ADJACENT TO 
IACH ACTIVITY HD'l'IONED. IF U ACTIVITY HENTIONED IS NOT 
ON TBE LIST,. nlTE IT II', IN TD RESPORDEHT' S OVll WORDS, 
Df TBE SPACE PROVIDED} 
Can you think of any other activities you have done 
during the last 2 weeks that have made you feel short of 
breath? 
[RECORD ADDITIONAL ITEHS1 
2. I vill now read a list of activities which make some 
people vith lung problems feel short of breath. I vill 
pause after each item long enough for you to tell me if 
you have felt short of breath doing that activity during 
the last 2 weeks. If you haven't done the activity 
during the last 2 weets, just answer "NO'. The 
activities are: 
[READ lTEHS, OHITTING THOSE VlICH RESPONDENT BAS 
VOLtnfTEDEJ) SPONTANEOUSLY. PAUSE AFTER IACH lTD TO GIVE 
RESPOIDEHT A CIWtCE TO IHDlCATE VIE1'JIEI II/SHE HAS BEEN 
SHORT OF BREATH VIlLE PERFORMING THAT ACTIVITY DURING THE 
LAST VEEl. CIRCLE TIE NUHBER ADJACENT TO APPROPRIATE 
ITEHS ON ANSVER SHEET] 
1. BEING ANGRY OR UPSET 
2. BAVING A BATH OR SBOVER 
3. BDDING 
4. CURYING, SUCB AS CARRYING GROCERIES 
5 • DRES SING 
6. DTING 
7. GOIBG FOR A VALK 
8. DOING YOUR. BOUSnOlUt 
,. IUIlIIlfG . 
10. JWalfG A BED 
11. HOPPDG 01 SCRUB8IlfG TD FLOOR 
12. IOVDG FUJUflTURE 
13. PL.lYIIG VITH CBILDID OR GUJmClIILDRD 
14. PLAYIlfG SPORTS 
15. UlCBIlfG OVER YOUI BDJ) 
16 • RURJIDG, SUeB IS rOR A 8US 
17. SBOPPING 
18. VIILB T1YIl'fG TO SLEEP 
19. TlLIDfG 
20. n,uuKING 
21. DLnllG 1R.0mm YOUI on BOlE 
22. 1lILmG UPBILL 
23. 1llLIDfG UPSTAIRS 
24. IlLJtIHG UTH O'1'BERS ON LEVEL GROmm 
25. PREPARING IEALS 
. 
3.a) Of the it ... which you have listea, which is the most i,portant to 
you in your aay-to-aay life~ I will reaa through the it ... , ana 
when·I am finishea, I woula lite you to tell me which is the most 
ilIportan t. . 
[RIAD TDOUGB ALL ITDS SPOH'J'lDOUSLY VOLUIfiKUD lHD THOSE 
nOI THE LIST nICS PATIENT KDfIORED] 
ihich of these it... is most iaportant to you in your aay-to-
aay life? 
[LIST ITEM ON RESPOBSE SHEft] 
))) Of the reaaining it ... , which is the .ost iaportant to you in your 
aay-to-aay life? I will read through the it ... , ana when I am 
finishea, I woula like you.to tell ae which is the .ost iaportant. 
[lEAD TBIlOUGB REDDmfG ITDS] 
llhich of these items is most iaportant to you in your aay-to-aay 
life? 
[LIST ITEM ON RESPONSE SBEET] 
.c) Of the remaining items, which is most important to you in 
your day-to-day life? 
«1) 
e) 
[LIST ITEM ON RESPONSE SlEET] 
Of the remaining items, which is the most iaportant to 
you in your day-to-day life? 
[LIST ITO ON RESPONSE SHEET] 
Of the rellaining items, which is the most important to 
you in your day-to-day life? 
[LIST InK ON U:SPONSE SHEET] 
[FOR ALL SUBSIQUEHT QUESTIONS, ElSUlE U:SPOIDER'1' BAS 
APPROPRIA'1'I OSPONSI ClI]) IN noft OF '1'1ID allORI 
STARTING QUESTION] 
4. I would now like you to describe how auch shortness of 
breath you have experienced during the last 2 weeks while 
doing the five 1I0St important activities you have 
selected. 
a) Please indicate how much shortness of breath you have had 
during the last 2 weeks while [INf.ElVIIVII: INSERT ACTIVITY 
LIST IN la] by choosing One of the following options froa the 
card in front of you: [GREll CARD] 
1 IX'l'RDELY SHORT OF aR.'EA'l'B 
2 VERY SHORT OF aREA'l'B . 
l QUI'l'I A aIT SHORT OF alEAT.! 
4 KODIRA'l'E SHORTNESS OF alEA'l'B 
5 SOKE SHORTNESS OF aREA'l'B 
6 A LI'l"1'LE SHORTNESS OF aREA'l'B 
7 NOT A'1' ALL SHORT OF aREA'l'B 
b) Please indicate how much shortness of breath you have had 
during the last 2 weeks while [IlTERtIiiER: INSIlT 
ACTIVITY LISTED IN lb] by choosing one of the following 
options froll the card in front of you: [GlEER CARD] 
1 IX'l'RDELY SHORT OF aREA'l'B 
2 VERY SHORT OF allATH 
3 QUITE A aIT SHORT OF aREA'l'B 
4 KODEllTE SHORTNESS OF aREl'l'B 
5 SOK! SHORTNESS OF alEA'l'B 
6 A LITTLE SHORTNESS OF aREATH 
7 HOT AT ALL SHORT OF aREATH 
c) Please indicate how much shortness of breath you have had 
during the last 2 weeks while [IHTERVIEVER: IHSERT 
ACTIVITY LIST IN 3c] by choosing one of the following 
options from the card in front of you: [GREEN CARD] 
1 EXTREMELY SHORT OF BREATH 
2 VERY SHORT OF BREATH 
3 QUITE A BIT SHORT OF BlEAT! 
4 KODERATE SHORTNESS or BlEAT! 
5 SOKE SHORTNESS OF BREATH 
6 1 LITTLE SHORTNESS OF BlEAT! 
7 HOT 1T ALL SHORT or BREATH 
d) Please indicate how much shortness of breath you have had 
during the last 2 weeks while [IITIIVIEVER: IHSERT 
1CTIVITY LISTED IH 3d] by choosing one of the following 
options from the card in front of you: [GREER CARD] 
1 EX'l'lDELY SHORT or BREATH 
2 VERY SHORT or BREATH 
3 QUITE 1 BIT SHORT or BlEATH 
4 HO~ER1TE SHORTNESS or BREATH 
5 SOKE SHORTNESS or BKEATH 
6 1 LITTLE SHORTNESS or BREATH 
7 HOT 1T ALL SHORT or BREATH 
e) Please indicate how much ~hortness of breath you have had 
c\uring the last 2 weeks while [Dft'ElYlElfER: INSERT ACTIVITY 
.~STED IN 3e] by choosing one of the following options from 
the card in front of you: ·[GlEEN CllD] 
1 EXTREHELY SHORT or BREATH 
2 VERY SHORT or BREATH 
3 QUITE 1 BIT SHORT or BREATH 
4 KODERATE SHORTNESS or BREATH 
5 SOKE SHORTNESS or BREATH 
6 1 LITTLE SHORTNESS or BREATH 
7 HOT 1T ALL SHORT or BIEATH 
5. In general. how much of the tiae during the last 2 weeks have 
you felt frustrated or iapatient? Ple .. e indicate how often 
durin; the last 2 weeks you have felt frustrated or impatient 
by choosing one of the following options from the card in 
front of you: [BLUE CARD] 
1 ALL or THE TIKI 
2 KOST OF THE TIKI 
3 A GOOD BIT OF THE TIKI 
4 SOKE OF THE TIKE 
5 1 LITTLE OF THE TIME 
6 HlRDLY ANY OF THE TIKE 
7 NONE OF THE TIKE 
6. How often durin; the past 2 weeks did you have a feel in; of 
fear or panic when you had difficulty gettiAg your breath? 
Please indicate how of teA you had a feeliAg of fear or panic 
vheA you had difficulty gettiAg your breath by choosiAg OAe of 
the following optioAS fro. the card iA froAt of you: [BLUE 
CAID] 
1 ALL or Tn: TID 
2 !lOST or Til TIKI 
3 A GOOD BIT or Tn: TIlE 
4 SOKE or Tn: TIllE 
5 A LITTLE or Tn: TIllE 
6 HAlDLY AllY or Tn: TIKE 
7 HONE or Tn: TI!IE 
7. What about fatigue? low tired have you felt over the 
last 2 weeks? Please iAdicate how tiTed you have felt 
over the last 2 weeks by choosiAg OAe of the followiAg 
options from the card iA froAt of you: [OIlRGB CAlD] 
1 IXTIDELY TIlED 
2 VDY TIltED 
3 gum: A BIT or TIlEDHlSS 
4 HODEU.TELY TIlED 
5 SOHEWD.T TIlED 
6 A LITTLE TIlED 
7 HOT AT ALL TIlED 
8. -BoY of teA duriAg the last 2 .eeks have you felt 
embarrassed by your coughiAg or heavy breathiAg? Please 
iAdicate hoy much of the time you felt embarrassed by 
your cough1Ag or heavy breathiAg by choosiAg OAe of the 
followiAg optioAS from the card 1A froAt of you: [BLUE 
C1llD] 
1 ALL OF TIB TID 
2 !lOST or TIE TIlE 
3 A GOOD BIT or Tn: TIKI 
4 SOD or TIE TIHE 
5 A LITTLE OF TIE TIllE 
6 IWtDLY AllY or TIl TIKI 
7 NONE OF TIE TIm: 
9. In the last 2 weeks. how much of the time did you feel 
very confident and sure that you could deal with your 
illness? Please indicate how much of the time you felt 
very confident and sure that you could deal with your 
illness by choosing one of the following options from the 
card in front of you: [YELLOV ClID) 
1 Ion or TO TID 
2 . 1 LI'f"rLB or TIE TIKI 
l SOD or TBE TID 
4 1 GOOD lIT or TD TID 
5 KOST or TIE TIKE 
6 lLKOST ALL or TIE TID 
7 ALL or TIE TDIE 
10. Boy much energy have you had in the last 2 weeks? Please 
indicate how much energy you have bad ~y choosing one of the 
following options from the card in front of you: [PIIX CARD] 
1 10 EHDGY 1T ALL 
2 1 LITTLI DDGT 
3 SOD ERElGY 
4 KODERATELY ERDGBTIC 
5 QUITE 1 lIT or DDGY 
6 VDY DElGZTIC 
7 FULL or DEltGY 
11. In general, how much of the time did you feel upset. 
worried, or depressed during the last 2 weeks? Please 
indicate how much of the time you felt upset, worried. or 
depressed during the past 2 weeks ~y choosing one of the 
following options from the card in front of you. [BLUE 
CUD] 
1 ALL or TIl TID 
2 HOST or TIl TDIE 
l 1 GOOD lIT or TO TDIE 
4 SOD or TIl TID 
5 1 LITrLE or TIl TID 
6 IlUDLY DY or TIE TID 
7 I'ORB OJ' TIE TID 
12. How often during the last 2 weeks did you feel you had 
complete control of your breathing problems? Please 
indicate hoy often you felt you had complete control of 
your breathing problems by choosing one of the following 
options from the card in front of you: [YELLOV CARD] 
1 HONE or Tn: TIU 
2 A'LITTLE or THE TIU 
3 ' SOKE or THE TIKE 
4 A GOOD BIT or THE TIU 
5 lOST or THE TIXE 
6 AL!OST ALL or THE TIXE 
7 ALL or THE TIXE 
13. How much of the time during the last 2 weeks did you feel 
relaxed and free of tension1 Please indicate how much of 
the time you felt relaxed and free of tension by choosing 
one of the following options fro. the card in front of 
you: [YELLOV CARD] 
1 HONE or· TIE TIXE 
2 1 LITTLE or THE TIU 
3 SOKE or THE TIXE 
4 A GOOD BIT or THE TIU 
5 lOST or THE TIU 
6 ALKOST ALL or THE TID 
7 ALL or THE TIllE 
14. How often during the last 2 weeks have you felt low in 
'energy? Please indicate how often during the last 2 
weeks you have felt low in energy by choosing one of the 
following options from the card in front of you: [BLUE 
CARD] 
1 ALL or THE TDa: 
2 lOST or THE TIKI 
3 1 GOOD BIT or THE TIXE 
4 SOKI or TIE TDa: 
5 1 LITTLE or THE TIME 
6 JWlDLY ANY or THE TIME 
7 HORE or TBE TIm: 
15. In general, how often during the last 2 weeks have you 
felt discouraged or dowu in the dumps? Please indicate 
how often during the last 2 weeks you felt discouraged or 
down in the dumps by choosing one of the following 
options from the card in front of you: [BLUE CARD] 
1 ALL OF THE TIHE 
2 HOST OF THE TIHE 
l A GOOD BIT OF TBI TID 
4 SOKI OF TBI TIKI 
5 A LIT'rLI OF Til TIll 
6 nuLY 1lfY OF TIlE TID 
7 HOlE OF T!I TIKI 
16. Bow often during the last 2 weeks have you felt worn out 
or sluggish? Please indicate how .uch of the tiae you 
felt worn out or slu,gish by, choosin, one of the 
following options from the card in front of you: [BLUE 
C1JU)] 
1 ALL OF TBI TIKI 
2 KOST OF TIE TIll 
l A GOOD BIT OF TBI TIKI 
4 SOD OF TIlE Tnm ' 
5 A LITTLE OF THE TIllE 
6 nuLY U'Y OF Til TIKI 
7 ROlE OF TIl TIHI 
17 •. Bow happy~ satisfied, or pleased have you been with your 
personal life during the last 2 weeks? Please indicate 
how happy, satisfied or pleased you have been by choo.ing 
one of the following options fro. the card in front of 
you: [GUY CARD] 
1 VElY DISSATISFIED~ URIlPPY KOST OF THE TID 
2 GIlfEIJJ·J·Y DISS.lTISFIID, UlIUPPY 
l SOiliDT DISSATISFID, URDPPT 
4 GIIElALLY SATISFIID, PLEASD 
5 BUPY KOST or TIE TID 
6 VElY HAPPy HOST or TIl TIlE 
7 IXTlIKELY UPPY. COULD IfOT BAYE BID' HoaE SATISFIED OR 
PJ..EASIl) 
18. How often during the last 2 weets did you feel upset or 
seared when you had difficulty getting your breath? 
Please indicate how often during the past 2 weeks you 
felt upset or seared when you had difficulty getting your 
breath by choosing one of the following options from the 
card in front of you: [BLUE ClID] 
1 ALL 01 TIE TIB 
2 - HOST 01 THE TID 
3 1 GOO» BIT or TIE TID 
4 SOlIE 01 Tn Tna: 
5 1 LITTLE or TIE TID 
, I.UJ)LY AHY or TBE ·TIIIE 
7 BORE 01 TIE TID 
19. In general, how often during the last 2 .eets haye you felt, 
-restless, tense, or uptight? Ple .. e indicate how often you 
haye felt restless, tense, or uptight by choosing one of the 
following options fro. the card in front of you: [BLUE ClID] 
1 .ILL or TIE T11II 
2 HOST or TIE Tna: 
3 A GOO» BIT or TO TIllE 
4 SOKE 01 TIB TID 
5 A LITTLE OJ' TIl TID 
, 1WU)L! BY or TO TIllE 
7 BORE or 'I'D TIKI 
cia RISPORSI SBIET 
1. BBIlIG UGlY 01 UPSET 
2. DVIlIG A lAm OR SB01lElt 
3. BIIDIBG 
4. CUlYIBG r SUCI AS C.lI.IYIlIG GROCDIIS 
5. DUSSDlG 
6. DUBG 
7. GODG!'OR A VILI" 
8. DODG TOua loumon 
9. IUBlIIBG 
10. pmG A BD 
11. JIOPPDG 01 SClUBBIRG TJlB FLOOR 
12. IIOJIIG FOUmJII 
13. PLlUJIG 1ll'1'I CBILDID 01. GI.IlIDCJIlLDIEI 
14. PLAXIlG SPORTS 
15. wgmG 01'D TOua JIIlD 
16. Jt1I1!IIDG, SUCB AS roa A BUS 
17. SBOPPIBG 
18. IBILB DYIlIG TO SLEEP 
19. %ll.nJfG 
20. DeUUmG 
21. VlLlDG UOUID TOua OD BOD 
22. !!I.me UPIILL 
23. D'kITMG UPS'rJ.DS 
24. !!teRRG 1ll'1'I OTJIDS Olf LBVBL GaOUlD 
25. PUPlRDG IDLS 
OTBIR ACTIVITIIS 
Activity 3a) 
Activity 31» 
Acti'l'ity 3c) 
Actiyity 3d) 
Activity 3e) 
CHRONIC RESPIRATORY DISEASE INDEX QUESTIONNAIRE 
Follow-up, 7 Point Scale, Informed 
You have previously completed a questionnaire(s) telling us about 
how you were feeling and how your lung disease was affecting your 
life. This is a follow-up questionnaire designed to find out how 
you have b~en getting along the last [insert length of time since 
last seen]. 
Vben you are answering the questions this time I will tell you the 
answer you gave us the last time. I would like you to give your 
answer today keeping in mind what you said the last time. For 
example. let's say that last time I asked you how short of breath 
you were While beating carpets [GIVE IESPOKDIIT GlEEK CUD] and you 
said "4 loderate shortness of breath". If you were exactly the 
saae today, you would answer 4 once again. If you were more short 
of breath you would choose 1, 2, or l and if you were less short of 
breath you would choose 5, 6, or 7. 
[FOR QUESTIONS 4a) to 4e) INSERT ACTIVITIES la) to le)FROH FIRST 
ADKINISTIATION AHSVER. SlEET] 
4. I would now like you to describe how much shortness of 
breath you have experienced during the last two weeks 
while doing each of the five most important activities 
you have selected • 
.. a) Please indicate how much shortness of breath 
you have had during the last two weeks while 
[nrrD.VIEVER: INSERT ACTIVITY LISTED IN la] by 
choosing one of the following options fro. the 
card in front of you. keeping in aiDd that last 
time you answered the questionnaire you chose 
[INSD.T PAnDT'S U'SRl FlOIl PREVIOUS 
ADIWfISTUTIOlf]. [GRIIIf CUD] 
b) Please indicate how much shortness of breath 
you have had during the last two weeks while 
[IlfTDVIEVD: INSDT ACTIVITY LISTED IN lb] by 
choosing one of the following options from the 
card in front of you. keeping in mind that last 
time you answered the questionnaire you chose 
[INSERT PATIENT'S 1BSVER. FIOK PREVIOUS 
ADKIHISTIATION]. [GRIIIf CUD] 
c) Please indicate bow mucb sbortness of Dreatb 
you bave bad during tbe last two weeks wbile 
(INTERVIEWER: INSERT ACTIVITY LISTED IN lc] DY 
cboosing one of tbe following options from tbe 
card in front of you, keeping in mind tbat last 
time you answered tbe questionnaire you cbose 
[INSERT PATIENT'S ANSVEl FRO! PREVIOUS 
1DKINISTItATION] • [GltEEN CUJ)l 
d) Please indicate bov mucb shortness of breatb 
you bave had during the last tva weeks vhile 
(IHTDVIEVD: INSERT ACTIVITY LISTED II 3d) by 
choosing one of tbe following options from the 
card in front of you, keeping in mind that last 
time you ansvered the questionnaire you chose 
[INSIIT PATIERT'S AlSVEl rROK PREVIOUS 
ADJWfISTUTION]. [GDEI ClllD] 
e) Please indicate hov much shortness of breath 
you had during the last two weeks vhile 
(DitU.VDVn: INSERT ACTIVITY LIS'tED m 3e] by 
choosing one of the folloving options from the 
card in front of you, keepiDg in mind that last 
time you answered the questionnaire you chose 
[INSERT PATIENT'S AlSVEl rROK PREVIOUS 
lDIIDfISTItATION] • [GUD CUJ)] 
5. In'general, hov much of the time during the last tvo 
weeks have you felt frustrated or impatient? Please 
"inclicate how often during the last tvo weeks you have 
felt frustrated or impatient by choosing one of the 
folloving from the card in front of you, keeping in mind 
that last time you answered the questionnaire you chose 
[mSOT P1TIElfT' S ANSVEl FROK PlEVIOUS AD!IID'STItATIOI]. 
[ILUE CUD] 
6. low often during the past two veeks did you have a 
feeling of fear or panic vhen you had difficulty getting 
your breath? Please indicate how often you had a feeling 
of fear or panic vhen you had difficulty getting your 
breath by choosing one of the following options from tbe 
card in front of yeu keeping in mind that last time you 
ansvere4 the questionnaire you chose [DiSOT PATIElfT'S 
lKSVD rROK PREVIOUS AD!I1ISTllTIOlf]. [BLUE C1ltD] 
7. What about fatigue? lov tired have you felt over the 
last two veeks? Please indicate hov tired you have felt 
over the last tvo weeks DY choosing one of the following 
options from the card in front of you, keeping in mind 
tbat last time you ansyered the questionnaire you cbose 
[IISOT PATIENT'S ANSVER FRO! PREVIOUS AD!IIISTRATION]. 
[OlWfGE CARl)] 
8. How often during the last two weeks have you felt 
embarrassed by your coughing or heavy breathing? Please 
indicate how much of the time you felt embarrassed by 
your coughing or heaving breathing by choosing one of the 
following options from the card in front of you, keeping 
in mind that last time you answered the questionnaire you 
chose [IBSERT PATIENT'S ANSVEI rlOK PREVIOUS 
ADKIlfISTUTIOlf]. [BLUE CARD] 
9. In the last two weeks, how much of the time did you feel 
very confident and sure that you could deal with your 
illness? Please indicate how lIuch of the tille you felt 
very confident and sure that you could deal with your 
illness by choosing one of the following options from the 
card in front of you, keeping in Dind that last time you 
answered the questionnaire you chose [IBSElT PATIENT'S 
llfSVER. rlOK PUVIOUS ADKIHISTUTIOH]. [TlLLOV' CAlD] 
10. Bow lIuch energy have you had in the last two weeks? 
Please indicate how lIuch by choosing one of the following 
options froll the card in front of you, keeping in mind 
that last time you answered the questionnaire you chose 
[INSERT PATIENT'S AHSVIl FlOK PUVIOUS ADKIHISTIlTIOH]. 
[PIHlt CUD] 
11. In general, how much of the tille did you feel upset, 
worried or depressed during the last two weeks? Please 
indicate how much of the tille you felt upset, worried, or 
depressed during the last two weeks by choosing one of 
"the following options froll the card in front of you. 
keeping in mind that last tiae you answered the 
questionnaire you chose [IISElT PATIENT'S ABSVEl rlOH 
PREVIOUS ADHIHISTlATIOll]. [BLUE CARD] 
12. Bow often during the last two weeks did you feel you had 
cOllplete control of your breathing problells? Please 
indicate how often you felt you had cOllplete control of 
your breathing probleas by choosing one of the following 
options froll the card in front of you, keeping in mind 
that last tille you "answered the questionnaire you chose 
[IBSERT PATIENT'S ANSWEI rROK PlEVIOUS ADKIlISTIlTIOH]. 
[YILLOV' CAlD 1 
13. Bow much of the tille during the past two weeks did you 
feel relaxed and free of tension? Please indicate how 
lIuch of the tille you felt relaxed and free of tension by 
choosing one of the folloring options froll the • card in 
front of you, keeping lIind that last tille you answered 
the questionnaire you chose [IHSERT PATIENT'S ANSVER FROK 
PREVIOUS ADHIHISTlATIOll]. [YELLOv CA1D] 
14. Bow often during the last two weeks have you felt low in 
energy? Please indicate how often during the last tva 
weeks you have felt low in energy by choosing one of the 
following options from the card in front of you, keeping 
in mind that last time you answered the questionnaire you 
chose [INSERT PATIENT'S ANSVER rlOM PREVIOUS 
ADHIHISTATION]. [BLUE CARD] 
15. In general, how often during the last two weeks have you 
felt discouraged or down in the duaps? Please indicate 
how often during the last two weeks you have felt 
discouraged or down in the duaps by choosing one of the 
following options from the card in front of you, keeping 
in mind that last time you answered the questionnaire you 
chose [IISERT PATIENT'S lNSVEl FROK PREVIOUS 
ADHIlfISTRATIOlf] • [BLUE CARD] 
16. Bow often during the last two weeks have you felt worn 
out or sluggish? Please indicate how much of the time 
you felt worn out or sluggish by choosing one of the 
following options from the card in front of you, keeping 
in mind that last time you answered the questionnaire you 
chose [IISERT PATIENT'S AHSVEl FROM PREVIOUS 
ADHINISTRATION]. [BLUE CAlD] 
17. Bow happy, satisfied, or pleased have you been with your 
personal life during the last two weeks? Please indicate 
how happy, satisfied or pleased you have been by choosing 
one of the following options fro. the card in front of 
"you, keeping in mind that last time you answered the 
questionnaire you chose [IRSElT PATIERT'S lMSVEl FlOM 
PREVIOUS ADHIlfISTRATION]. [GRAY CARD] 
18. Bow often during the last two weeks did you feel upset or 
scared when you had difficulty getting your breath? 
Please indicate how often during the last two weeks you 
felt upset or scared when you had difficulty getting your 
breath by choosing one of the following options froa the 
card in front of you, keeping in aiDd that last time you 
answered the questionnaire you chose [IRSElT PATIENT'S 
AJlSllEl rlOK P1EVIOUS ADKIlfISTlATION]. [BLUE CAlD] 
19. In general, how eften during the last two weeks have you 
felt restless, tense, or uptight? Please indicate how 
often you have felt restless, tense, or uptight by 
choosing one of the following options fro. the card in 
front of you, keeping in mind that last tiae you answered 
the questionnaire you chose [INSERT PATIENT'S AlfSVER raOH 
P1EVIOUS ADMINISTRATION]. [BLUE CARD] 
IQY!1i:t.i.20_! 
4a) 
4bi 
4c:; 
4d) 
4e) 
6. 
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-7. 
18. 
del. 
dl. 
112. 
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114. 
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le. 
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